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1  Introduction 
1.1 Drug design 
The origin of many diseases or their symptoms is the dysregulation of 
particular proteins in certain organs and cells of the human body. The basic 
concept in drug design is that the activity of these proteins can be artificially 
modulated through the binding of a drug to these assigned target proteins.  
However, the development of such an approved drug is an expensive process 
that on average takes 13.5 years (example from 2007) and capitalized costs of 
around $ 1,778 million.1 An acceleration and cost reduction could be achieved 
if the prediction of successful drug candidates in the early stage of 
development was improved. Hence, the major challenge we are facing 
nowadays, is to reliably predict a drug’s in vivo efficacy, its potential for 
resistance development and success in clinical trials.  
With respect to this topic, a paradigm shift could be witnessed over the last 
couple of years. The classical approach in drug design is to solely optimize 
the affinity between a drug candidate and its target protein in the process of 
drug development. Nonetheless, many recent studies suggest that affinity 
between the target protein and a drug alone is not the best descriptor for a 
drug’s in vivo effectiveness and success.  
Additional biophysical descriptors such as thermodynamics and kinetics of 
ligand binding to the target protein are taken into account with increasing 
popularity over the last years (Figure 1). These additional parameters allow 
further differentiation of drug candidates early on in the development 
 process.2 Nonetheless,
particular application 
Furthermore, the detailed 
modifications of potential drugs really influence kinetics or thermodynamic 
signatures of protein binding
predictions it is crucial to use and characterize model systems as detailed as 
possible. Consequently there is a strong requirement for extensive and 
systematic investigations of drug
understanding and hence
design.       
Figure 1: Systematical investigation of various protein
interactions is required to understand the interplay between 
structure, thermodynamics, kinetics an
have to interact in order to produce an optimal drug
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 it is still under discussion in what direction 
these biophysical parameters should be optimized. 
understanding on how rational chemical 
 is still insufficient. In order to 
-target interaction in order to gain 
 improve predictive power for the process of drug 
d affinity and how they 
. 
2 
for a 
enable these 
 
-ligand 
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The essence of drug design is the induction of an optimal drug binding 
process to the target protein leading to an ideal drug-protein interaction. 
This binding is a highly complex process that is influenced by factors like 
shape complementarity, hydrogen bonding, van der Waals forces, and 
changes in protein, drug and protein-drug complex hydration, flexibility and 
degrees of freedom. In total, the binding affinity reflects the strength of the 
protein-drug interaction. In the following small molecule drugs, potential 
drug in the development process, as well as fragments thereof, are referred to 
as “ligands” or “compounds”. 
1.2 Thermodynamics & isothermal titration 
calorimetry 
As described above, thermodynamic analysis of protein-ligand complex 
formation is used with increasing popularity as an additional descriptor in 
the process of drug design. To measure thermodynamic profiles the method of 
isothermal titration calorimetry (ITC) is frequently applied and also 
employed in this thesis to measure the thermodynamic signature of different 
protein-ligand complexes. The schematic set-up of an ITC experiment is 
depicted in Figure 2. 
 Figure 2. Schematic set
stirring of the syringe paddle
cell which is filled with protein
or absorption of heat. The reference cell is filled with water and kept at a 
constant temperature.
 
The ITC device features two cells 
contains the protein sample (sample cell) the other contains water as a 
reference (reference cell). Both cells are then heated to an equal, user
temperature. A constant power is applied to the reference cell to mai
the defined temperature. 
a ligand-solution is titrated into the 
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-up of an ITC experiment. Under continuous 
, the ligand is stepwise titrated into the sample 
. The protein-ligand binding leads to a release 
 
located within an adiabatic jacket
During the measurement, a small, defined volume of 
sample cell. The binding reaction then 
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, one cell 
-defined 
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either releases or absorbs heat. Hence the power applied to the sample cell 
needs to be modified in order to achieve the same temperature as the 
reference cell (feedback power). For exothermic ligand binding, less power is 
required, for endothermic ligand binding the power applied needs to be 
increased. The differential power is proportional to the difference in 
temperature between the two cells and is recorded.3 
Multiple aliquots of ligand solution are stepwise titrated into the sample cell. 
Each injection causes a peak shaped heat signal (Figure 3). Peak integration 
after the measurement yields a sigmoidal curve. From this curve association 
constant Ka, stochiometry n and enthalpy of binding ΔH° can be read. ΔG° 
can then be calculated from KA using the definition of Gibbs free energy of 
binding for a system at chemical equilibrium, where R is the ideal gas 
constant (8.314 J mol-1 K-1) and T the absolute temperature (K)4: 
∆° = −	
K 
The entropic contribution –TΔS° consisting of the change in entropy ΔS° (kJ 
mol-1), which is weighted by the temperature, is then calculated from ΔG° 
(kJ mol-1) and ΔH° (kJ mol-1) using5: 
∆° = ∆° − ∆° 
Therefore, only ΔG° and ΔH° are directly determined. Entropy is merely 
calculated and therefore the most error-prone parameter. 
The symbol “°” indicates a binding free energy value in its standard state and 
is often neglected for convenience. The reference of the standard state is 
essential for scaling and comparing different measurements. The standard 
state is defined for 1 mole ligand and 1 mole protein forming 1 mole protein-
 ligand complex. The reaction takes place in a hypothetical ideal solution 
having a unit activity coefficient at a constant pressure of p°=10
Figure 3. ITC-thermogram. The top graph depicts the different 
injection peaks during the titration (exothermic signal). 
graph shows the sigmoidal curve resulting from peak integration. In this way, 
the experimental values K
obtained. 
 
1.3 Enthalpy vs. entropy
As described above, 
enthalpy ΔH and entropy 
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a, ΔH and the stochiometry of the reaction are 
 
the Gibbs free energy of binding ΔG partitions into 
–TΔS. Thereby, enthalpy is a measure for the 
6 
5 Pa.6 
 
The lower 
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amount of heat energy required to reach a certain state, while entropy 
reflects how easily this energy can be dispensed throughout various molecular 
energy levels.4 
A favorable enthalpy for a ligand-protein complex formation can result from 
favorable hydrogen bonds, the quality of which is defined by their distances 
and angles. Also van der Waals interactions can have a beneficial impact on 
enthalpy. They mostly result from hydrophobic interactions and desolvation. 
The desolvation of polar groups on the other hand has an unfavorable effect 
on the entropic contribution.4 
Concerning entropy, binding of two partners to form one common complex 
inevitably results in an entropic penalty that has to be overcome. Upon 
binding, the system looses half of its translational and rotational degrees of 
freedom. Moreover, the ligand and partially also the protein looses 
conformational degrees of freedom. However, an increase in buried 
hydrophobic surface through ligand binding, resulting in a release of water 
from the active site, is considered entropically favorable (hydrophobic 
effect).4 
Due to enthalpy-entropy compensation optimizing both terms unfortunately 
remains challenging. A system with improved specific interaction and hence 
improved enthalpy is usually less dynamic, resulting in a, partially 
compensating, unfavorable entropy.7 
1.4 The physiological relevance of PKA 
The cAMP-dependent protein kinase (PKA) is used as a model protein in 
this thesis. Its ample implication in physiologically important signalling 
1. Introduction 
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pathways makes PKA unsuitable as a drug target. Potential side effects 
could be severe. However, this kinase is well investigated, can be expressed in 
large quantities, crystallizes easily and can be used for protein NMR as well 
as SPR measurements. Hence it is the perfect model protein for systematic 
kinase studies. 
PKA is physiologically activated downstream of membrane integrated G-
protein coupled receptors (GPCR). Through receptor stimulation outside the 
membrane, GPCRs can bind and thereby activate the stimulatory Gs-protein. 
The Gs-protein is a heterotrimer consisting of an αs-, β- and γ-subunit. The 
αs-subunit can bind Guanosindiphosphate (GDP) as well as 
Guanosintriphosphate (GTP). Upon activation, GDP is exchanged for 
cytosolic GTP and the βγ-complex as well as the GPCR is separated from 
the αs-subunit. The remaining αs-GTP complex then activates adenylyl 
cyclase at the inside of the membrane, leading to an increased conversion of 
ATP into cyclic adenosine monophosphate (cAMP). This rise in the cAMP 
level can then activate PKA.8 In its inactive state, PKA is a heterotetramer 
and consists of two regulatory and two catalytic subunits. The regulatory 
subunits can cooperatively bind two molecules of cAMP. Binding of cAMP 
leads to a conformational change resulting in a release of the two separate 
catalytic subunits. Upon release, the activated catalytic subunits can then 
phosphorylate serine and threonine residues of various substrate proteins. 
These phosphorylations regulate a wide range of signaling pathways further 
downstream of PKA. 9 
For instance, PKA is involved in glycogen metabolism and it stimulates gene 
expression by phosphorylating the transcriptional activator cAMP-response 
 element binding (CREB) protein. Furthermore, PKA can phosphorylat
potassium channels in neurons,
increasing excitability of the cell.
strongly depend on the cell type.
1.5 The structure 
Overall, kinase structure
terminal lobe with 5 β
region with the larger C
helices. The active site is located in
Figure 4. Crystal structure of PKA from 
with ATP. The hinge region is colored in green, Gly
DFG-loop in purple. In the active site 
ions (physiologically Mg
bank (PDB), code 1ATP
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 thereby facilitate their closing
10 Generally, the effects of PKA signali
 
of PKA 
s are widely conserved. Kinases consist of a small N
-sheets. The small lobe is connected through the hinge 
-terminal lobe which is predominately build from α
-between the two lobes.11  
mus musculus
-loop in blue and the 
ATP is bound together with two Mn
2+ ions). The structure is taken from the protein data 
12. 
9 
e 
, leading to an 
ng 
-
-
 
 in complex 
2+ 
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The entire kinome can be divided into nine families. PKA itself belongs to 
the AGC-kinase family of serine/threonine kinases.13 All 63 kinases included 
in this group respond to changes in local concentrations of cytoplasmic 
second messengers such as cAMP or lipids.14 
In Figure 4, the general fold of PKA is visualized; the most important 
elements for ATP- and ligand-protein interaction are colored. Physiologically, 
the adenine ring of ATP is positioned in a deep hydrophobic pocket between 
the small and big lobe and forms hydrogen bonds to the hinge region (green). 
Two magnesium ions, essential for ATP binding, enable the positioning of 
the negatively charged ribose-triphosphate tail. Thereby the γ-phosphate that 
is transferred in the catalytic process is located at the edge of the catalytic 
cleft. It is stabilized by the glycine-rich loop (Gly-loop) (blue) and the DFG-
loop (purple). Another conserved sequence involved in substrate recognition 
is the APE-motif which located in the C-terminal substrate recognition 
pocket. 
Hinge, Gly-loop and DFG-loop are also crucial interaction sites for ATP-
competitive kinase inhibitors and will be referred to in the following chapters 
of this thesis. The hinge region is the most essential drug interaction partner, 
possessing two donor and one acceptor function in nearly linear 
arrangement.15 The Gly-loop is highly flexible and can adopt closed and 
opened conformations. Crucial for the activity and for so-called DFG-out 
inhibitors is the DFG-loop. If the phenylalanine from the DFG-motif is 
rotated out of the binding pocket, a kinase is in its inactive conformation. 
Some ligands are able to trigger this conformation. However, for PKA so far 
1. Introduction 
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no DFG-out conformation has been observed, hence it remains unclear 
whether PKA can adopt such a conformation. 
 
1.6 Aim of the thesis 
This thesis is subdivided into six parts. The first four chapters focus on 
systematic thermodynamic and structural examination of drug-kinase 
interactions.  
Protein-drug interaction is analyzed using cAMP-dependent protein kinase 
(PKA) as a model protein. The use of well-studied model proteins allows 
capturing elaborate information from a wide range of experimental 
techniques. Therefore, PKA is a prototype of the wide and clinically relevant 
protein kinase family. The human genome might encode for up to 518 protein 
kinases.13 Many of these kinases might be of pathological relevance. 
Anomalous kinase activity is particularly important in diseases that originate 
from inflammatory and proliferatory responses. Examples are cancer, 
rheumatoid arthritis, cardiovascular and neurological disorders, asthma and 
psorias. These implications make protein kinases indeed a major target in 
drug design.16-18 
Here, the aim was to investigate the interaction of PKA with different ligand 
subsets. Even though all ligands derive from the approved drug fasudil, they 
each focus on different structural aspects relevant in drug design. Through 
minor structural changes in the ligand compositions, major changes in 
protein-ligand complex structure and thermodynamics of binding can be 
caused. With this approach current theories can be tested on their 
1. Introduction 
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applicability in the field of protein kinase inhibition. Aspects analyzed in the 
first four chapters are the impact of ligand degrees of freedom, changes 
resulting from ligand growth, the possible influence of methyl groups 
decorating the ligands in various positions, and differences in the hinge 
binding modes of the ligands. The hinge region, being in the active site of the 
protein, is the crucial area of attack for ATP-competitive kinase inhibitors. 
The fifth chapter focuses on the issue of kinase selectivity. A kinase screen 
was performed and thermodynamic data were checked for correlation with 
selectivity profiles. Current hypotheses on the topic should be experimentally 
tested.  
The sixth chapter is a methodology analysis. It aims at comparing the two 
major crystallization methods: Soaking and co-crystallization. Using PKA as 
an example, pronounced structural differences were observed. 
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2 The Surprising Impact of Flexibility on 
Drug-Kinase Interaction 
2.1 Annotations 
The following chapter will be published. It is a cooperation of the groups of 
Prof. Gerhard Klebe and Prof. Harald Schwalbe. The following people 
contributed to the subject and will therefore be listed as authors on the 
publication: 
Barbara Wienen-Schmidt‡, Hendrik R. A. Jonker†, Tobias Wulsdorf‡, Hans-
Dieter Gerber‡, Krishna Saxena†, Andreas Heine‡, Harald Schwalbe†*, 
Gerhard Klebe‡* 
‡Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, 
Marbacher Weg 6, 35032 Marburg, Germany 
†Institut für Organische Chemie und Chemische Biologie, Johann Wolfgang 
Goethe-Universität Frankfurt, Max-von-Laue-Straße 7 , N160-3.14 , 60438 
Frankfurt am Main, Germany 
* Corresponding authors 
Protein expression for ITC and crystallization was performed by Barbara 
Wienen-Schmidt as well as ITC-measurements, crystallization and crystal 
structure determintion. Ligand synthesis and qNMR measurements were 
performed by Hans-Dieter Gerber. Amide chemical shift perturbations as well 
as amide 15N-T2-relaxation measurements and related protein expression 
were performed by Henry Jonker. 
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2.2 Abstract 
Considering biophysical parameters in drug design can accelerate and direct 
the development of clinically successful drugs. Currently, the selection of 
drug candidates with particular thermodynamic and kinetic profiles upon 
binding is under discussion and even prevalently applied. One such concept is 
the design of rigid ligands in order to reduce the entropic penalty upon 
binding to the target protein. Nonetheless, systematic studies analyzing to 
what extent ligand rigidity influences the overall thermodynamic profile are 
deficient. In this study, the effect of ligand flexibility on the thermodynamic 
profile of ligand binding to a protein was investigated. For this purpose, the 
wide and clinically relevant family of protein kinases is represented by 
cAMP-dependent protein kinase (PKA). All ligands derive from the approved 
drug fasudil and have an equal number and scope of atom types of 
heteroatoms while varying in their internal degrees of freedom. Protein-ligand 
interactions were scrutinized using X-ray crystallography, isothermal titration 
calorimetry (ITC) and nuclear magnetic resonance spectroscopy (NMR). 
Three different aspects that influence the resulting thermodynamic profile 
were checked: 1. Protein-ligand complex flexibility, 2. Ligand flexibility and 
3. Protein-ligand complex hydration. From our results we conclude, that 
protein-ligand complex flexibility does not differ significantly for our series of 
ligands even though a strong induced fit is observed. Interestingly, ligand 
flexibility and hence the loss of degrees of freedom upon binding does in no 
way dominate binding thermodynamics. Water however, more detailed the 
change in protein-ligand complex hydration, as well as differences of ligand 
hydration in aqueous solution prior to binding seem to be the crucial factors 
and are essential to consider for the general understanding of thermodynamic 
2. The Surprising Impact of Flexibility on Drug-Kinase Interaction 
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profiles of ligand binding. Altogether, our results demonstrate that protein-
ligand interactions for flexible proteins are even more complex than for rigid 
proteins. Our data demonstrate that global understanding and potential 
future prediction of thermodynamic profiles are highly dependent on further 
systematic studies.  
2.3 Introduction 
Finding selective, effective and clinically successful drugs is a long and 
expensive enterprise. Hence, it would be beneficial if this process could be 
accelerated by improving criteria to predict successful drug candidates and to 
identify unsuitable ones early on. Therefore, the analysis of parameters 
beyond affinity is required. In this context thermodynamic analysis of 
protein-ligand interaction is used with increasing popularity. Accordingly, the 
design of drugs with certain thermodynamic properties has been described as 
a promising approach in many articles and reviews.1-6 Moreover, design 
guidelines to accomplish purposefully tailored profiles have been intensely 
discussed, frequently advising the development of rigid, correctly 
preorganized ligands in order to influence the entropic penalty upon binding 
of the ligand to its target.7-10, 2  
However, there remains a lack of systematic studies that explore correlations 
between ligand structure, target protein characteristics and thermodynamic 
signature. From our perspective, it is important to distinguish between 
different types of proteins. An utter generalization cannot lead to satisfactory 
answers. Particular factors that have to be taken into account are: 1. Size; 2. 
Flexibility of the target and 3. Water structures. In this study we 
thermodynamically investigated the wide and clinically relevant family of 
2. The Surprising Impact of Flexibility on Drug-Kinase Interaction 
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protein kinases. Protein kinases are highly flexible proteins 11-13 as indicated 
by the presence of flexible loops in the active site and helix movement upon 
ligand binding. They have been rarely investigated by means of 
comprehensive thermodynamic characterization. Only ten unique kinases are 
listed in databases that are specialized for thermodynamic annotations, such 
as Scorpio14 and BindingDB15 (CDK2, ERK1/2, JNK2, Pim1, Aurora-A, 
Thymidine Kinase, Nucleosid Diphosphate Kinase, vSrc, cSrc). Indeed for 
none of these targets has a systematic investigation of ligand series been 
conducted. Considering that according to Manning the human genome might 
encode for up to 518 protein kinases16 and with respect to their importance as 
a drug target class, there is a clear need for thermodynamic data to 
characterize protein kinases. The aim of this study is to start filling this gap, 
in order to broaden our understanding of kinase dynamics and 
thermodynamics of ligand binding. 
Here, the use of well-studied model proteins allows for the capture of 
extensive information from a wide range of experimental techniques. Using 
the cAMP-dependent protein kinase (PKA) as a model system, elaborate 
information on protein-ligand interaction was obtained using X-ray 
crystallography, isothermal titration calorimetry (ITC) and nuclear magnetic 
resonance spectroscopy (NMR). The selected ligands are derived from the 
approved drug fasudil17, which has been developed as a rho-kinase 
inhibitor18 but, nonetheless, displays high affinity toward PKA19. All of these 
ligands have an equal number and scope of atom types of heteroatoms but 
vary in their internal degrees of freedom (Figure 1). In this way, the effect 
of ligand flexibility on the thermodynamic protein binding profile can be 
investigated. Thorough analysis of the underlying structural factors 
2. The Surprising Impact of Flexibility on Drug-Kinase Interaction 
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contributing to this thermodynamic profile has been made using X-ray 
crystallography and 1H15N best-TROSY (transverse relaxation optimized 
spectroscopy) spectra. Furthermore, protein-ligand complex dynamics were 
analyzed using 15N-T2-relaxation measurements. Here, we present a unique 
study where the static data from high resolution crystal structures is faced 
and combined with the information on the dynamics from detailed NMR 
measurements. 
For the thermodynamic data, ITC was used to measure ΔG and ΔH. 
Subsequently, –TΔS was calculated using the expression for Gibbs free 
energy of binding: 
∆ = ∆ − ∆ 
The KD was determined from ΔG using the definition of Gibbs free energy 
for a system at chemical equilibrium: 
∆ = −	  1 
The variables have the subsequent definitions: ΔG: Gibbs free energy of 
binding; ΔH: Enthalpy of binding; ΔS: Entropy of binding; R: Ideal gas 
constant; T: Absolute temperature; KD: Dissociation constant. 
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Figure 1. Chemical structure of the five ligands used in this study. 
All ligands have an equal number of heteroatoms but different
conformational degrees of freedom. From the left to the right the internal 
degrees of freedom increase and will, in any case, require an entropic price to 
be paid upon binding, as an increasing number of torsional degrees of 
freedom will be lost. In purpl
derivative (Ligand 01
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Our study displays striking results that could hardly have been predicted, as 
counterintuitively the most flexible ligand binds entropically most favorably 
to the protein. Consequently, the hypothesis stating 
a ligand’s degrees of freedom is detrimental with respect to the entropic 
contribution to binding, needs to be questioned and analyzed in the context 
of the entire binding event. We conclude that a generalization of simple 
design guidelines is not constructive an
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2.4 Experimental section 
Protein expression and purification 
The catalytic subunit of cAMP-dependent protein kinase from Chinese 
hamster ovary cells was expressed with a His-tag in a modified pET16b-
Vector with an introduced TEV-cleavage site between the protein N-terminus 
and His-tag. This plasmid was transformed into E. coli strain Bl21 
(DE3)/pLysS (Novagen).20 
Cell disruption was performed using a high-pressure homogenizer for multiple 
cycles. After centrifugation (1h at 30.000g) cell lysate supernatant was 
purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with a sodium chloride gradient.20 
Crystallization 
Co-crystallisation was performed using the hanging drop method at 4 °C. The 
crystallization drops contained the following ingredients: 10 mg/mL PKA 
(240 µM), 30 mM MBT (MES/Bis-Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM 
EDTA, 75 mM LiCl, 0.03 mM Mega 8, 0.07 mM PKI (Sigma: P7739), 1.2 
mM ligand dissolved in DMSO from a 50-100 mM stock. The well contained 
a mixture of methanol in water with varying methanol concentrations (v/v) 
for the different ligands (Fasudil: 18% methanol; Ligand 05: 18% methanol; 
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Ligand 04: 14% methanol; Ligand 01: 16% methanol; Ligand 02: 19% 
methanol). In the crystallization setup streak-seeding was performed with 
apo-crystals as seeds using a horse hair in order to initialize crystal growth. 
For crystal mounting, crystals were cryo protected in 5 mM MBT (MES/Bis-
Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM LiCl, 1.2 mM ligand dissolved in 
DMSO from a 50-100 mM stock, 16 % (v/v) methanol, 30% (v/v) MPD and 
flash frozen in liquid nitrogen. 
Crystallography 
All structures were collected at the storage ring Bessy II Helmholtz-Zentrum 
Berlin, Germany at Beamline 14.1 on a Pilatus 6M pixel detector. The 
datasets were processed using XDS21 and molecular replacement was 
performed using CCP4 Phaser22 and PDB-structure of PKA from bos taurus 
1Q8W as a model. This was followed by simulated annealing, multiple 
refinement cycles of maximum likelihood energy minimization and B-factor 
refinement using Phenix23. Coot24 was used to fit amino-acid side chains into 
σ-weighted 2Fo – Fc and Fo – Fc electron density maps. If appropriate 
electron density was observed, multiple side chain conformations were built 
into the model and maintained during the refinement if the minor populated 
side chain displayed at least 20 % occupancy. Hydrogen atoms were included 
using a riding model. Ramachandran plots for structure validation were 
calculated using PROCHECK25. Data collection, unit cell parameters and 
refinement statistics are given in the supplementary information. Analysis of 
temperature factors was performed with Moleman26. Protein and PKI B-
factors were anisotropically refined, water B-factors were isotropically refined 
for all structures. Decision for anisotropic or TLS refinement was based on 
comparison of Rfree. Anisotropic refinement was chosen over TLS if the 
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achieved Rfree values were at least 0.5% lower for anisotropic than for TLS 
refinement. Rfree was calculated using 5% of all reflections which were 
randomly chosen and not used for the refinement. The required ligand 
restraint files were created using the Grade webserver27, 28. For figure 
preparation Pymol was used.  
Isothermal titration calorimetry 
The buffer used for the ITC experiments contained: 30 mM sodium 
phosphate buffer pH 7.2, 10 mM MgCl2, 100 mM NaCl, 3% (v/v) DMSO. All 
measurements were repeated 3-5 times. Further buffers were used in order to 
check for protonation linkage. In these buffers 30 mM sodium phosphate 
buffer was replaced by 30 mM HEPES and 30 mM triethanolamine (TEA), 
respectively (both at pH 7.2). Buffer dependency was tested for all 
measurements in the absence of PKI. For the measurements expressed, 
purified and dialyzed PKA was used in the ITC-measuring cell. A 15-20 fold 
higher concentrated ligand solution, diluted in dialysis buffer, was then 
stepwise injected to the protein solution during the measurement. All 
measurements were performed at 25 °C. ITC data were analyzed using 
NITPIC and Sedphat29, 30. Raw data and exact values and standard 
deviations for ΔG, ΔH and -TΔS can be found in the supplementary 
information. 
Compound purity was analyzed using quantitative nuclear magnetic 
resonance spectroscopy (qNMR) and in case of deviation, ligand 
concentration was corrected accordingly. 
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NMR 
All protein NMR measurements were performed by the group of Prof. Harald 
Schwalbe in Frankfurt/Germany. 
Ligands 
Ligands 01, 05 and 04 were purchased from Uorsy (Ukraine). The R and S 
isomers of the 2-methylpiperazine inhibitors 01 and 02 were synthesized 
starting from 5-(chlorosulfonyl) isoquinoline-hydrochloride prior to this 
freshly prepared from isoquinoline-5-sulfonic acid via a known literature 
procedure31, 32, which was reacted with the respective, commercially available, 
enantiomerically pure R or S-configured mono-N-Boc-protected 3-
methylpiperazine thus rendering the corresponding inhibitor precursors, 
respectively. Final N-Boc deprotection with 4 M HCl in dioxane gave rise to 
the corresponding inhibitors 01 and 02 as their hydrochloride salts. 
2.5 Results 
Strongest induced fit is triggered by the most flexible ligand. In 
order to verify comparable binding modes of all five ligands discussed, co-
crystal structures were obtained. For all structures, resolutions between 1.4 
and 1.6 Å could be achieved. In all five cases, difference electron densities are 
well defined and indicate every heteroatom of the bound ligands 
(supplementary information) with 100% occupancy in the binding site. All 
structures have been deposited in Protein Data Bank (PDB). The respective 
codes are listed in Table 1. 
Importantly, the crystallographic data confirmed that indeed all five ligands 
display a congruent hinge binding position of their respective isoquinoline 
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moiety (Figure 2B). Moreover, their adjacent sulfonamides occupy a 
common orientation in all structures, where one oxygen points toward the 
Gylcine-rich loop (Gly-loop) and the second toward the hinge region. Hence, 
protein-ligand interactions are highly similar for the isoquinoline-5-
sulfonamide portions of all five ligands. In all structures, a hydrogen bond is 
formed between the isoquinoline-nitrogen of the ligands and the backbone 
nitrogen of Val 123 of the protein. Besides these interactions, the compounds’ 
sulfonyl-groups do not directly interact with the protein. 
Table 1. List of PDB-codes for the different ligand co-crystal 
structures 
Ligand PDB code 
Ligand 01 5LCU 
Ligand 02 5LCT 
Fasudil 5LCP 
Ligand 04 5LCR 
Ligand 05 5LCQ 
 
In contrast to the identical ligand core binding, significant changes were 
noted amongst the five different protein-ligand-complexes considering the 
attached sulfonamide substituents. 
In particular, the αG helix, the APE motif and the position of the protein-
kinase-inhibitor-peptide (PKI) are visibly shifted (Figure 2A). Yet, the 
most prominent difference was revealed in the active site. Here, the Gly-loop 
adopts three distinct positions ranging from a wide-open to a closed 
conformation when compared to the apo-protein (Figure 2B). 
The first, most open position of the Gly-loop exhibits the structure with the 
open-chained ligand 04 (red). Here, the loop is pushed out of the ligand 
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binding site as result of steric hindrance. The binding of ligand 
requires more space in the area of the Gly
Figure 2. Superimposition of the co
ligands. A: Overall view of the protein. Ligand 
fasudil in green; 02 in blue; 
the active site. The long
change dragging the Gly
and the protein are displayed as orange dotted lines. The key interaction 
responsible for the downward movement of the Gly
to Thr51. This transition is facilitated by the new interactions formed by the 
Gly-loop to the remaining part of the protein. The latter contacts are 
displayed as black dotted lines.
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The second, half-open conformation of the Gly-loop is found in the structures 
of S-methyl-piperazine substituted ligand 01 (purple), the R-methyl-
piperazine substituted ligand 02 (blue) and fasudil (green). Interestingly, all 
three ligands share a common position of the Gly-loop even though the 
interaction pattern of the homopiperazine moiety and 2-methyl-piperazine 
moieties of the ligands with the protein differ significantly as will be 
described later.  
Finally, the third, closed position is depicted in the structure of the long-
chain ligand 05 (orange). A strong induced fit resulting in a pulling-down of 
the Gly-loop can be observed. Responsible for this rearrangement are two 
hydrogen bonds formed between the backbone oxygen of Thr 51 and the 
sulfonamide-nitrogen as well as the secondary amine in the long chain of the 
ligand as shown in Figure 2C. Only in ligand 05 is a secondary amide 
present in the sulfonamide position and it can hence act as a hydrogen-bond 
donor. All other ligands possess a tertiary amide as an equivalent, which does 
not have the ability to act as a hydrogen-bond donor. Consequently, the 
formation of the key interaction to Thr51 is impossible for all other 
compounds. In addition, steric hindrance would prevent the closed position of 
the Gly-loop for all ligands other than ligand 05.  
In the case of ligand 05, the closed conformation of the Gly-loop is facilitated 
by additional interactions of the loop involving the following amino acids of 
the protein: Asp184, Ser53 and Lys72. In total, five new interactions are 
formed (Figure 2C, black dotted lines). 
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Figure 3: Polar interactions 
protein structure. Ligand 
02 in blue; ligand 01
are represented as dotted lines and colored in conformity with the 
corresponding ligand. A:
of the protein. B: The different polar interactions of the five ligands 
additional to those shown in 
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From further analysis of the ligand binding mode, differences can be 
discerned with respect to the deviating substituents (Figure 3). The 
interaction patterns established by the terminal amines differ. The highest 
number of polar interactions to the protein is recognized by the 
homopiperazine portion of fasudil (green) and the terminal aminoethyl 
moiety of the open-chain ligand 04 (red). Interestingly, both ligands form 
comparable interaction patterns. In either case, the terminal amino group 
forms hydrogen bonds with the backbone carbonyl oxygen of Glu 170 as well 
as the terminal carboxamide or carboxylate group of the side chains of 
Asn171 and Asp184. In contrast to fasudil (green) and 04 (red), the 
interaction pattern of the terminal aminoethyl nitrogen of the long-chain 
ligand 05 (orange) differs. The only common interaction occurs with the 
backbone carbonyl oxygen of Glu 170. Furthermore, 05 interacts with the 
side chain of Glu127. 
It is also notable that the S-methyl-piperazine substituted 01 (purple) and 
the R-analog 02 (blue) each establish one hydrogen-bond to Asp 184 of the 
DFG-loop via their terminal NH group. 
A difference in the position of water molecules of the residual solution 
pattern can be observed for the different complexes. As a matter of fact, the 
protein flexibility takes impact on the observability of the adjacent water 
positions. By optimizing the diffraction quality of the studied crystals, the 
resolution of the collected datasets was maximized. Nonetheless, many 
putative water molecule positions remained unresolved due to an ambiguous 
density distribution next to the region showing enhanced residual mobility in 
the crystal structure. A distinct analysis and quantification of the water 
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pattern and hence a comparison across the active sites of all complexes is 
limited due to the flexible nature of the protein, which effects the electron 
density in this region. 
The most flexible ligand binds entropically most favored to the 
protein. The thermodynamic signature of ligand binding to the protein was 
determined using ITC. All profiles were assessed for putative buffer 
dependence. No significant protonation effects were observed in these 
experiments. The selected buffers differ in their ionization enthalpy by 
approximately 30 kJ/mol.33 A slope between -0.07 and -0.15 could be 
observed for 01, 05 and 04, across the three considered buffers, a value 
considered as insignificant. For 01 and 02, a slope of +0.15 was revealed. 
The calculated pKa value for the piparazine nitrogen is 7.3, which is slightly 
below the applied buffer pH (calculated using http://www.chemicalize.org/). 
Hence, there might be a slight protonation effect, owing to a partial proton 
uptake, in particular if compared to the slopes of the other compounds which 
have calculated pKa values between 8.0 and 10.1. However, also this amount 
of proton uptake is hardly beyond the significance threshold. Nonetheless, the 
profiles used for the evaluation of the thermodynamic signatures were 
determined in phosphate buffer to profit from the very low ionization 
enthalpy of this buffer. In literature values between 0.93 and 5.12 kJ/mol 
were reported as heat of ionization for the phosphate group33. 
To reveal a closer match with the crystallographic data we applied two 
distinct scenarios during the ITC titrations, both potentially important under 
physiological conditions. In the first set of titrations, the ligand was directly 
titrated to the protein in the sample cell. In the second set of titrations an 
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alternative strategy was used: A peptide sequence of the substrate protein to 
be phosphorylated was added to protein in the sample cell. In our 
experiment, a 20 residu
this peptide binds at the same position in the active site, adjacent to the 
ATP-binding site, as the substrate proteins. PKI mimics the amino acid 
sequence motif of the substrate proteins exhibiting as on
replacement of the Ser/Thr residue that becomes phosphorylated by an Ala.
Accordingly, measurements were performed in the presence (squared 
symbols) and absence (circular symbols) of the substrate
peptide PKI (Figure 
Figure 4. Thermodynamic profiles 
(circles) and presence of PKI (squares)
axis and enthalpy on the X
mean ΔG values of 32 kJ/mol. Titrations with the different ligands are 
colored according to the color
symbol for ligand 04 (red) is virtually hidden as the
fasudil (green). 
 
-Kinase Interaction
e peptide named PKI was applied. It is assumed that 
ly difference the 
-mimicking inhibitor 
4).  
for all five ligands in absence 
. Entropy is displayed on the Y
-axis. The dotted line represents isoaffinity for the 
-code presented in Figure 1
 same profile is found
 
31 
 
 
-
. The squared 
 for 
2. The Surprising Impact of Flexibility on Drug-Kinase Interaction 
32 
 
Upon comparison of the relative differences of the two sets of thermodynamic 
profiles it is apparent that on an absolute scale an offset between the sets of 
profiles is given leading to a shift toward more favorable entropy and less 
beneficial enthalpy in the presence of PKI (squared symbols). Thus, the 
relative differences between the ligands correlate in both cases and the 
ligands bind with equal potency. 
Moreover, it is striking that the binding signatures of fasudil (green), the 
two methyl-piperazine substituted 01 (purple) and 02 (blue) as well as the 
open-chain ligand 04 (red) are similar and scatter maximally in ΔΔH=4.2 
kJ/mol and –TΔΔS=7.8 kJ/mol. In comparison, the long-chain ligand 05 
(orange) displays a unique thermodynamic profile significantly reduced in its 
enthalpic and simultaneously enhanced in its entropic contribution to 
binding. In consequence, 05 was the most entropically and least enthalpically 
favorable binding ligand. In case of the presence of PKI, the effect concerning 
ligand 05 is similar, however, somewhat less pronounced. 
Correlation of amide chemical shift perturbations in presence and 
absence of PKI. To further analyze the structural influence of the peptidic 
inhibitor PKI, which is present in all of the studied crystal structures, 1H15N 
best-TROSY spectra were measured and the amide chemical shift 
perturbation (CSP) of 82 amino acids was analyzed in the presence and 
absence of PKI. Figure 5 shows the chemical shift perturbations from the 
1H15N-best-TROSYs in the absence and presence of PKI for the five different 
ligands. For clearity, the graph only depicts the largest shifts. These data 
indicate unchanged structural properties and demonstrate the relevance of 
the crystal structures determined in presence of PKI.  
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the strongest shift; X
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peptide. These NMR data fully support the structural information from 
crystallographic analysis. The residues with the smallest amide CSPs are: Arg 
45, Gly 66, Val 219, Gly 225, Val 266, Glu 245, Arg 280, Asp 301, Val 310, 
Glu 311, Asp 328, Glu 341, Cys 343, Gly 344. The structural alignment of the 
crystal structure in Figure 2 was performed using the backbone atoms of 
these 14 residues, thereby ensuring an authentic alignment. 
The most flexible ligand does not form a flexible protein-ligand 
complex. In order to analyze the residual flexibility of the resulting protein-
ligand complexes 15N-T2-relaxation NMR measurements were performed. 
Overall 75 amino acids could be assigned and are averaged in Figure 6. The 
15N-T2-relaxation time can be used as a direct measure for backbone 
dynamics, as the lower the 15N-T2-relaxation time is determined, the more 
rigid the protein backbone will be. We assume that the 15N-T2-relaxation 
times are representative for the dynamic properties of the entire amino acid 
residues. On average, the dynamics of all five complexes are very similar. It is 
striking that ligand 05 with the largest amount of internal degrees of freedom 
does not form a significantly more flexible protein-ligand complex compared 
to the other more constraint members of the series. 
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Figure 6. Amide 15
amino acids for the different ligands, res
are small. Error bars present the averaged standard deviation of the different 
amino acids. 
 
2.6 Discussion 
For a series of five congeneric ligands studied in this contribution we 
thoroughly analyzed the interaction with PKA. Hig
crystallographic data revealed a comparable hinge binding mode of all 
ligands. As special feature a strong induced
(orange) is observed. Thermodynamic signatures were measured either in the 
absence or in the presenc
uncover that ligand 05
unraveled the structural influence of PKI on the protein and allowed analysis 
of the backbone dynamics.
On first sight, it appears coun
(orange) exhibiting the largest amount of internal degrees of freedom, was 
the most entropically favored binder in the presence as well as absence of 
PKI. At first glance, this appears contradictory as the binding
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and conformationally preorganized ligands reveals an entropic advantage to 
binding.34, 35 In the present case, this would be expected for the ligands 
fasudil, 01 and 02 possessing the conformationally restricted cyclic 
substituents. The in contrast observed entropically more favored binding of 
ligand 05 to the protein can therefore result from multiple factors: Either 
from a protein-ligand complex with strongly enhanced residual flexibility, 
from the displacement of a larger number of water molecules from the active 
site upon ligand binding to the uncomplexed protein, or a difference in the 
solvation properties among the five ligands in aqueous solution prior to 
binding. This contribution even overcompensates the entropic losses to be 
paid by restricting the flexible ligand 05 to the bound state. The results from 
15N-T2-relaxation NMR measurements suggest however, that 05 forms the 
most rigid protein-ligand complex (Figure 6). This is in accordance with the 
crystallographic data indicating a strong induced-fit adaptation pulling the 
Gly-loop toward the bound state. Furthermore, this ligand shows the lowest 
overall B-factors in the crystal structure when compared to the other ligands 
(supporting information). Clearly this does not indicate an entropic 
advantage of 05 upon binding. One possible explanation for the favorable 
entropy contribution of ligand 05 can originate from displacement of 
previously well-ordered water molecules from the formed protein-ligand 
complex. Unfortunately, the amount of water molecules in the active site 
cannot be reliably evaluated due to a less-well defined electron density in 
that area of the crystal structures in consequence of enhanced loop flexibility. 
It is remarkable that the relative differences in the thermodynamic profiles 
between the five ligands remain similar with and without the substrate-like 
PKI. However, the overall shift on absolute scale appears reasonable 
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assuming that the protein is pre-stabilized and structurally organized in a 
way to better recognize either the co-substrate ATP or, in our case, the 
inhibitors of the fasudil-type upon binding of the substrate peptide. The 
thermodynamic profiles of ligand binding are all shifted toward an 
entropically more favorable but enthalpically less beneficial signature in the 
presence of PKI. This profile is in accordance with a better preorganization of 
one of the binding partner, here of the recipient protein.  
An alternative or additional contribution influencing the thermodynamic 
signature of ligand 05 compared to the other members of the series can arise 
from differences of the ligands in aqueous solution prior to binding. Once the 
ligands are released from the bulk water phase and accommodate the protein, 
they have to shed their solvation shells. If these shells show structural 
differences in the local solvation pattern, deviating thermodynamic signatures 
will result. In the present case, 05 would assemble a higher ordered local 
water structure which upon collapse will produce an entropic advantage. 
In conclusion, the experimental data demonstrate that the entropically more 
favored binding of 05 to the protein can only result from an 
overcompensating displacement of a larger amount of ordered water 
molecules from the active site upon ligand binding or an entropic benefit of 
the ligand while leaving the solvation shell in the bulk water phase. Our 
observation that a ligand with a larger amount of internal degrees of freedom 
does not necessarily lead to entropically less-favored binding was also 
observed in other cases, however, without providing a conclusive 
explanation.36 Therefore, the hypothesis stating a significant impact of the 
ligand’s degrees of freedom on the entropic binding component, needs to be 
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questioned and clearly requires a more detailed analysis of the binding event 
as a whole. It demonstrates that simple design guidelines cannot be 
generalized and deserve a more careful consideration. 
2.7 Conclusion 
General and hypothetical design guidelines need to be systematically 
investigated for different protein classes. Rules that apply for small and rigid 
proteins do not necessarily apply for large or flexible proteins. From our 
systematic study on a protein kinase we conclude that the thermodynamic 
profile is not dominated by the loss of rotational degrees of freedom of the 
ligand. The hypothesis, that ligand rigidification necessarily results in 
significantly more entropic ligand binding profiles could not be confirmed. 
Strikingly, we even recorded the opposite trend in that the most flexible 
ligand was the most favorable entropic binder. Therefore, the loss of degrees 
of freedom of the ligand, which, as a matter of fact, has to be paid, does not 
necessarily dominate the thermodynamic profile of a flexible protein like a 
kinase. Furthermore, the effect of residual flexibility of the formed protein-
ligand complex appears to be minor in the studied case as all complexes 
under consideration show very similar NMR data. In fact, the dominant 
effect seems to be the displacement of ordered water molecules from the 
active site particularly in the complex where the Gly-loop folds upon the 
bound ligand or from structural differences in the solvation pattern of the 
ligands in the bulk water phase. These appear to be the crucial factors for the 
resulting entropically favored binding. In summary, our results demonstrate 
that protein-ligand interactions formed with flexible proteins are even more 
complex than with rigid proteins. Our data signalize that global 
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understanding and reliable predictions of thermodynamic profiles need a view 
on the entire binding event and require many more systematic studies of 
congeneric ligand series. 
2.8 Abbreviations 
Ala: alanine 
Asp: aspartate 
Arg: arginine 
ATP: adenosine triphosphate 
CHO: Chinese hamster ovary 
CSP: chemical shift perturbation 
DFG: aspartat-phenylalanin-glycin motif 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
EDTA: ethylenediaminetetraacetic acid 
Gly: glycine 
Gly-loop: glycine-rich loop 
Glu: glutamate 
His-tag: histidine-tag 
ITC: isothermal titration calorimetry 
MBT: MES/Bis-Tris 
MPD: 2-methyl-2,4-pentanediol 
Ni-NTA: nickel-nitrilotriacetic acid 
NMR: nuclear magnetic resonance spectroscopy 
PDB: protein data bank 
PKA: cAMP-dependent protein kinase 
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PKI: protein kinase inhibitor 
qNMR: quantitative nuclear magnetic resonance spectroscopy 
Ser: serine 
TEA: triethanolamine 
TEV: tobacco etch virus 
Thr: threonine 
TROSY: transverse relaxation optimized spectroscopy 
Val: valine 
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2.10 Supplementary information
Table S1. All atoms of all ligands were 100% occupied. For 
all five ligands are shown. 
Ligand 1, at 3.0 σ Ligand 2, at 2.8 σ
5LCU 5LCT 
  
Ligand 4, at 3.0 σ Ligand 5, at 3.0 σ
5LCR 5LCQ 
  
a) Density map shown at 2.8 σ in order to provide full visibility oft the ligand.
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visualiazation, σ-weighted 
a) Fasudil (Ligand 3), at 3.0 σ 
5LCP 
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Table S2. Crystallographic table for all crystal structures. Table spreads over two pages 
Ligand, PDB entry → 1, 5LCU 2, 5LCT 3, 5LCP 4, 5LCR 5, 5LCQ 
Data collection & processing      
No. Crystals used 1 1 1 1 1 
Wavelength [Å] 0.91841 0.91841 0.91841 0.91841 0.91841 
Space group 19 (P212121) 19 (P212121) 19 (P212121) 19 (P212121) 19 (P212121) 
Unit cell parameters: a, b, c [Å];  58.5, 73.0, 
109.4 
59.0, 73.7, 
109.8 
58.4 72.8, 
109.3 
58.3, 72.8, 
108.7 
57.9, 71.6, 
109.7 
Diffraction dataa)      
Resolution range [Å] 50.00-1.58 50.00-1.62 50.00-1.43 50.00-1.56 50.00-1.42 
Highest shell resolution range [Å] 1.68-1.58 1.71-1.62 1.52-1.43 1.66-1.56 1.51-1.42 
Unique reflections 61633 (9566) 61770 (9549) 84420 
(13201) 
64829 
(10151) 
84798 
(13274) 
R(I)sym [%]b) 5.8 (47.9) 4.8 (48.3) 4.1 (46.6) 6.8 (49.1) 5.7 (47.4) 
Completeness [%] 94.6 (92.2) 99.4 (96.4) 97.9 (95.8) 98.3 (96.4) 98.4 (96.5) 
Redundancy 3.4 (3.2) 6.5 (6.2) 4.0 (4.0) 4.0 (4.0) 4.0 (4.1) 
I/σ (I) 12.4 (2.1) 24.0 (3.5) 17.1 (2.5) 11.2 (2.1) 15.3 (2.7) 
Refinement      
Resolution range [Å] 43.77-1.58 46.1-1.62 39.90-1.43 39.75-1.56 34.04-1.42 
Reflections used in refinement (work/free) 58551/3082 58679/3091  80197/4223 61585/3244 80556/4242 
Final R values for all reflections (workc)/freed)) 
[%] 
15.2/19.2 14.3/17.4 13.3/16.6 15.5/19.7 14.1/17.1 
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a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck25 
Amino acids (PKA/PKI) 353/20 353/20 353/20 353/19 353/18 
Inhibitor atoms 20 20 20 20 20 
Water molecules 417 412 448 392 551 
RMSD from ideality      
Bond length [Å] 0.009 0.009 0.008 0.008 0.008 
Bond angles [°] 0.95 0.96 0.94 0.98 0.96 
Ramachandran plote)      
Residues in favoured regions 91.5 92.7 92.4 93.0 92.1 
Residues in additionally allowed regions [%] 8.5 7.3 7.6 7.0 7.6 
Residues in generously allowed regions [%] 0.0 0.0 0.0 0.0 0.3 
Mean B-factors [Å²]      
PKA (protein)/PKI (peptide) 23.8/24.8 25.4/26.9 24.3/23.8 25.3/23.6 16.6/14.9 
Inhibitor 18.4 22.7 19.2 21.7 12.1 
Water molecules 31.8 33.1 37.0 32.4 28.8 
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Table S3. Thermodynamic data for all ligands including the respective standard deviations (titration without 
PKI). 
 
 
 
 
Table S4. Thermodynamic data for all ligands including the respective standard deviations (titration with 
PKI). 
Ligand ΔG [kJ/mol] ΔH [kJ/mol] -TΔS [kJ/mol] 
1 -28.5±0.0 -16.2±0.3 -12.3±0.3 
2 -29.9±0.5 -17.9±0.6 -12.0±1.1 
Fasudil -32.8±0.1 -15.8±0.3 -17.0±0.4 
4 -32.6±0.5 -15.7±1.0 -16.9±1.5 
5 -31.5±0.4 -12.5±0.3 -19.1±0.7 
 
Ligand ΔG [kJ/mol] ΔH [kJ/mol] -TΔS [kJ/mol] 
1 -31.3±0.3 -35.7±1.0 4.3±1.3 
2 -31.9±0.1 -37.0±0.2 5.1±0.3 
Fasudil -36.1±0.3 -33.1±0.4 -3.1±0.7 
4 -35.4±0.5 -35.1±0.9 -0.3±1.4 
5 -32.0±0.3 -22.8±1.0 -9.2±1.3 
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Figure S2. ITC-titration curves for ligand 02 without PKI in p
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Figure S5. ITC-titration curves for ligand 05 without PKI in p
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3 Enthalpy is Losing it: Stepwise Ligand 
Growth and its Influence on Kinase-
Ligand Interaction 
3.1 Annotations 
The following chapter will be published. It is a cooperation of the groups of 
Prof. Gerhard Klebe and Prof. Harald Schwalbe. The following people 
contributed to the paper and will therefore be listed as authors on the 
publication: 
Barbara Wienen-Schmidt‡, Hendrik R. A. Jonker†, Tobias Wulsdorf‡, Hans-
Dieter Gerber‡, Krishna Saxena†, Andreas Heine‡, Harald Schwalbe†*, 
Gerhard Klebe‡* 
‡Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, 
Marbacher Weg 6, 35032 Marburg, Germany 
†Institut für Organische Chemie und Chemische Biologie, Johann Wolfgang 
Goethe-Universität Frankfurt, Max-von-Laue-Straße 7, N160-3.14, 60438 
Frankfurt am Main, Germany 
* Corresponding author 
Protein expression for ITC and crystallization was performed by Barbara 
Wienen-Schmidt as well as ITC-measurements, crystallization and 
crystallography. Computational analyses were performed by Tobias 
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Wulsdorf. Ligand qNMR analyses were performed by Hans-Dieter Gerber. 
Henry Jonker performed amide chemical shift perturbations analysis and 
amide 15N-T2-relaxation measurements and related protein expression. 
3.2 Abstract 
Here we present a unique fragment study focusing on the thermodynamics of 
fragment growth. Four ligands with increasing molecular weight and their 
interaction with cAMP-dependent protein kinase (PKA) were thoroughly 
analyzed. Strikingly, these ligands display affinities between nanomolar and 
low micromolar potency on PKA despite their low molecular weight. This 
allows a direct measurement of the binding thermodynamics via isothermal 
titration calorimetry (ITC). A direct measurement can rarely be reliably 
performed for fragments. Therefore, the presented data provide a valuable 
insight into fragment thermodynamics. Furthermore, protein-ligand 
complexes were structurally analyzed using crystallography and NMR in 
order to explain the observed changes in thermodynamics. The clear trend 
towards more entropic and less enthalpic binding upon increasing molecular 
weight results from structural changes as well as differences of the 
uncomplexed ligands in solution. The latter being a factor that has been 
utterly underestimated. 
3.3 Introduction 
Fragment based drug design (FBDD) has been applied with increasing 
popularity for the development of new drugs in academia and the 
pharmaceutical industry. It is often considered as an improved approach 
compared to the extremely expansive high-throughput screening (HTS) in 
order to generate first hits for a subsequent individually tailored ligand 
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optimization.1-4 Two frequently used strategies in FBDD are either fragment 
linking or fragment growing. In this contribution we present a systematic 
analysis of ligand properties following the process of ligand growing. 
Accordingly, four different ligands with stepwise increasing molecular weight 
are studied in detail in terms of their binding behavior (Figure 1). The 
cAMP-dependent protein kinase (PKA) is used as a model protein for our 
studies being a representative of the large clinically relevant class of protein 
kinases. 
Binding mode analyses of the ligands as well as putative changes of the 
protein conformation were assessed using either X-ray crystallography or 
nuclear magnetic resonance spectroscopy (NMR). Moreover, thermodynamic 
analysis was performed providing detailed information about the stepwise 
changes of the thermodynamic signatures during the gradual process of 
fragment growing. Thermodynamic data were recorded using isothermal 
titration calorimetry (ITC) applying a protocol of direct titrations under the 
condition of c-values between 5 and 70. Such values indicate that a crude 
sigmoid curve can still be recognized. 
The combined structural and thermodynamic data for fragment based 
approaches are still rare, but collection of such information is essential to 
improve our understanding of the ligand binding process.5 
The data presented in this study demonstrate a classical example of partial 
enthalpy-entropy compensation. Structurally observable changes in ligand 
binding modes as well as surprising differences in the properties of the ligands 
in solution prior to protein binding appear to be responsible for the observed 
differences of the thermodynamic signatures upon ligand binding. These 
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factors are crucial in fragment growing. They have to be considered as 
determining factors in the design process upon growing of a ligand into a 
protein binding site. 
Figure 1. Chemical structure of the four ligands used in this study
Molecular weight of the ligands increases from left to right.
1: isoquinoline-5-sulfonamide; in blue ligand 
methylisoquinoline-5-sulfonamide; in red ligand 
aminoethyl)isoquinoline
(propylamino)ethyl]isoquinoline
 
It has been hypothesized that increasingly larger ligands in contrast to 
fragments favor a more entropic binding. 
fragment binding would not increase with ligand size.
reasons to explain this observation that enthalpy dominated binding of 
fragments turns into a more entropy favored binding with growing ligand 
size. Discussed is for instance the impact of apolar desolvation that increases 
with ligand size due to a 
bond fit and an increased entropic penalty resulting from a mobility that 
decreases with the number of H
Furthermore, larger ligands do not only bind to protein hot
and its Influence on 
Kinase-Ligand Interaction 
 In purple ligand 
2: the methylated N
3: short chained N
-5-sulfonamide; in orange ligand 4: long
-5-sulfonamide 
Thus, the enthalpic component of 
6 There are s
reduced probability for an optimal geometrical H
-bonds between ligand and protein.
-
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beyond. These interactions outside protein hot-spots do not display as strong 
H-bond conservation as the hot-spots themselves. In fact, these interactions 
might play a role for the enthalpic component and binding selectivity.6 
Strikingly, even under consideration of the above discussed factors through 
size-independent ligand analysis methods such as the size-independent 
enthalpic efficiency-value (SIHE), the gain in enthalpy upon ligand growth 
remains noteworthy for the ligand set presented here. 
3.4 Experimental section 
Protein expression and purification 
The catalytic subunit of cAMP-dependent protein kinase from Chinese 
hamster ovary cells was expressed with a His-tag in a modified pET16b-
Vector with an introduced TEV-cleavage site between the protein N-terminus 
and His-tag. This plasmid was transformed into E. coli strain Bl21 
(DE3)/pLysS (Novagen).7 
Cell disruption was performed using a high-pressure homogenizer for multiple 
cycles. After centrifugation (1h at 30.000g) cell lysate supernatant was 
purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with a sodium chloride gradient.7 
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Crystallization 
Crystallization of 4 is discussed in the previous chapter. Co-crystallization 
was performed using the hanging drop method at 4 °C. The crystallization 
drops contained the following ingredients: 10 mg/mL PKA (240 µM), 30 mM 
MBT (MES/Bis-Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM EDTA, 75 mM 
LiCl, 0.03 mM Mega 8, 0.07 mM PKI (Sigma: P7739), 1.2 mM ligand (120 
µM for ligand 1) dissolved in DMSO from a 50-100 mM stock. The well 
contained a mixture of methanol in water with varying methanol 
concentrations (v/v) for the different ligands (01: 18% methanol; 02: 18% 
methanol; 03: 14% methanol). In the crystallization setup streak-seeding was 
performed with apo-crystals as seeds using a horse hair in order to initialize 
crystal growth. For crystal mounting, crystals were cryo protected in 5 mM 
MBT (MES/Bis-Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM LiCl, 1.2 mM 
ligand (ligands 2 and 3) or 120 µM (ligand 1) dissolved in DMSO from a 50-
100 mM stock, 16 % (v/v) methanol, 30% (v/v) MPD and flash frozen in 
liquid nitrogen. 
Crystallography 
Structures of 1 and 2 were collected at the storage ring Bessy II Helmholtz-
Zentrum Berlin, Germany at Beamline 14.1 on a Pilatus 6M pixel detector. 
Structure of 3 was collected at the European Synchrotron Radiation Facility 
(ESRF) Grenoble, France at Beamline 14. Structure of 4 is discussed in the 
previous chapter. 
The datasets were processed using XDS8 and molecular replacement was 
performed using CCP4 Phaser9 and PDB-structure of PKA from bos taurus 
1Q8W as a model. This was followed by simulated annealing, multiple 
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refinement cycles of maximum likelihood energy minimization and B-factor 
refinement using Phenix10. Coot11 was used to fit amino-acid side chains into 
σ-weighted 2Fo – Fc and Fo – Fc electron density maps. If appropriate 
electron density was observed, multiple side chain conformations were built 
into the model and maintained during the refinement if the minor populated 
side chain displayed at least 20 % occupancy. Ramachandran plots for 
structure validation were calculated using PROCHECK12. Data collection, 
unit cell parameters and refinement statistics are given in the supplementary 
information. Analysis of temperature factors was performed with Moleman13. 
Protein and PKI B-factors were anisotropically refined, water B-factors were 
isotropically refined for structure of 3. Structures of 1 and 2 were TLS-
refined. For the definition of the TLS groups the TLSMD server was used.14, 
15 Decision for anisotropic or TLS refinement was based on comparison of 
Rfree. Anisotropic refinement was chosen over TLS if the achieved Rfree values 
were at least 0.5% lower for anisotropic than for TLS refinement. Rfree was 
calculated using 5% of all reflections which were randomly chosen and not 
used for the refinement. The required ligand restraint files were created using 
the Grade webserver16, 17. For figure preparation Pymol was used. 
Crystallographic tables as well as mFo-DFc-densities of the different ligands 
can be found in the supporting information.For ligand 2 a second, allosteric 
binding site was found which was also 100% occupied. 
Calculation of polar and hydrophobic surfaces was done using the programme 
Molecular Surface.18-20 
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Isothermal titration calorimetry 
The buffer used for the ITC experiments contained: 30 mM sodium 
phosphate buffer pH 7.2, 10 mM MgCl2, 100 mM NaCl, 3% (v/v) DMSO. All 
measurements were repeated 4-7 times. Further buffers were used in order to 
check for protonation linkage. In these buffers 30 mM sodium phosphate 
buffer was replaced by 30 mM HEPES and 30 mM triethanolamine (TEA), 
respectively (both at pH 7.2). Buffer dependency was tested for all ligands 
and no significant buffer dependence could be detected. For the 
measurements expressed, purified and dialyzed PKA was used in the ITC-
measuring cell. A 15-20 fold higher concentrated ligand solution, diluted in 
dialysis buffer, was then stepwise injected to the protein solution during the 
measurement. All measurements were performed at 25 °C. ITC data were 
analyzed using NITPIC and Sedphat21, 22. Raw data can be found in the 
supplementary information. 
Compound purity was analyzed using quantitative nuclear magnetic 
resonance spectroscopy (qNMR) and in case of deviation, ligand 
concentration was corrected accordingly.23  
Ligands 
Ligands 1, 2 and 4 were purchased from Uorsy (Ukraine). Ligand 3 was 
purchased from Toronto Research Chemicals (Canada).  
NMR 
All protein NMR measurements were performed by the group of Prof. Harald 
Schwalbe in Frankfurt/Germany. 
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Computational analysis 
All atom MD (molecular dynamics) simulations were carried out for each 
compound. Each conformational ensemble was clustered into three clusters. 
Subsequently, MD simulations and GIST (grid inhomogeneous solvation 
theory)24 analysis were carried out in order to study the thermodynamics of 
water molecules bound on the surface of the ligand molecule in solution. 
MD simulation 
Compounds 1-3 were extracted from their pdb files with fconv25 and 
protonated with MOE (Molecular Operating Environment, Chemical 
Computing Group Inc., Montreal, Canada). Partial atomic charges were 
derived using multiconformational RESP fitting26 and Gaussian0927 on the 
HF/6-31+G level of theory. The programs antechamber and parmchk228 were 
used for assignment of gaff atom types and missing force field parameters. 
The compounds were solvated in a box of TIP4P-Ew water using tleap. 
All following MD steps were carried out using Amber14 and AmberTools14 
with periodic boundary conditions. Initially, each system was minimized with 
1000 steps of steepest descend followed by 5000 steps of conjugate gradient 
keeping the solute heavy atoms fixed with a 25 kcal/mol/Å² force constant 
followed by second minimization similar to the first one, but with force 
constant decreased to 5 kcal/mol/Å². After heating the system to 300 K the 
system was equilibrated while lowering the force constant. A final 5 ns NVT 
equilibration was carried out before starting production MD. All production 
MDs were run for 100 ns at 300 K in NVT ensemble using Langevin 
thermostat with a collision frequency of 1.0 ps-1. 
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Clustering 
The trajectories of the unbiased MD simulations were clustered into three 
distinct families using hierarchical agglomerative average-linkage clustering as 
implemented in cpptraj(V15.00)24. 
Restraint MD simulation 
Each cluster centroid was used as starting structure for further MD 
simulations. All preparation steps were similar to the former MD simulations, 
except that counter ions were placed randomly in 10Å distance to the 
compound. 
The minimization is similar to the one described before. During all following 
steps solute heavy atoms were constraint using a harmonic force constant of 
25 kcal/mol/Å². After heating to 300 K, equilibration in NPT (constant 
particles, pressure and temperature) was carried out for 5 ns followed by 5 ns 
of NVT (constant particles, volume and temperature) equilibration. 
Productive MD runs were carried for 50 ns. 
GIST analysis 
The trajectories obtained from the restraint MD simulation were analyzed 
with GIST as implemented in cpptraj. 
3.5 Results & discussion 
Higher molecular weight correlates with increasing entropy and 
decreasing enthalpy. As pointed out, the thermodynamic data were 
recorded through direct ITC titrations with reasonable c-values. A study 
under such conditions is indeed rarely possible for fragments owing to their 
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low binding affinity combinded with a minor heat signal indicating binding. 
In the current ligand series measurements provided reliable information on 
the binding thermodynamics. The thermodynamic profiles of the four 
different ligands binding to PKA are presented in Figure 2 and Table 1. A 
clear trend can be observed where entropy of binding increases with the 
molecular weight whereas enthalpy shows the reverse trend. The entropic 
contribution to the binding event is clearly increasingly unfavourable for 1 
and 2 and becomes more favourable for 3 and 4. 
In terms of affinity, 3 is the most potent inhibitor of PKA. The enthalpic loss 
upon the addition of the propyl-chain in ligand 4 cannot entirely be 
counterbalanced by the entropic gain. 
Table 1. Thermodynamic data and standard deviation for all four 
ligands. 
Ligand ΔG [kJ/mol] ΔH [kJ/mol] -TΔS [kJ/mol] 
1 -29.7±0.4 -38.7±2.5 9.1±2.9 
2 -27.9±0.4 -35.1±2.8 7.2±3.2 
3 -35.4±0.7 -31.8±0.6 -1.3±1.4 
4 -32.0±0.3 -22.8±1.0 -9.2±1.3 
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Figure 2. Thermodynamic signatures and observed trend (arrows) 
upon ligand growth.
(red arrow) becomes more favourable whereas enthalpy (green arrow) turns 
less beneficial. Error bars indicate standard deviation.
 
Increase of buried polar surface of the protein upon ligand growth.
Figure 3 shows the development of various surfaces for the different ligands. 
Surprisingly, we do not observe a classical hydro
described as the amount of water being displaced from the hydrophobic 
protein surface. Instead the proportion of buried polar protein surface (green) 
augments in parallel with the increasing surface of the growing ligands. This 
might explain why we see an in
decrease in enthalpy. The displacement of ordered water molecules which are 
mainly found in areas of the polar protein surface lead to a gain in entropy. 
However, the newly formed interactions between the growi
ligand and the protein might not be as geometrically and hence enthalpically 
and its Influence on 
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favorable as the original water
enthalpy throughout the series can be observed. 
Figure 3. Development of ligand surface and buried protein surface 
during fragment growing.
increasing ligand surface (bright blue) which in turn leads to a larger amount 
of total buried surface of the protein (dark blue). 
protein (green) surface also augments upon fragment growth, however the 
increase in hydrophobic buried surface of the protein (red) is noticeably 
smaller. 
Table 2. List of PDB
structures 
Ligand PDB code
1 5M0C 
2 5M0L 
3 5M0B 
4 5LCQ 
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Protein-ligand interaction pattern changes upon fragment growing. 
In order to fully understand the development of the thermodynamic 
signatures, a complete structural analysis of the entire system is necessary. 
Therefore, NMR spectroscopy as well as X-ray crystallography were used to 
receive a comprehensive structural picture. All crystal structures are 
deposited in the Protein Data Bank (PDB). The corresponding codes can be 
found in Table 2. Crystallographic results are shown in Figure 4 and 
Figure 5. Figure 4 visualizes the two different binding modes that can be 
observed for the four ligands. Interestingly ligands 1 and 2 share a common 
binding position (Figure 4A) where the nitrogen of the sulfonamide moiety 
forms a hydrogen bond to Asp127 (Figure 5B). Ligands 3 and 4 on the 
other hand not only display a slightly shifted binding position of the 
isoquinoline residue (Figure 4B) but show an entirely different interaction 
pattern of the sulfonamide moieties with the protein (Figure 5B). This 
sulfonamide portion is rotated around 80° compared to the orientation found 
for ligands 1 and 2 (Figure 4C). The longer alkyl chains, attached to the 
sulfonamides in ligands 3 and 4, sterically hinder the interaction to Asp127. 
Instead the sulfonamide-nitrogen in both cases forms a hydrogen bond with 
Thr51 of the glycine rich loop (Gly-loop) thereby pulling the loop into the 
active site. This interaction and position of the Gly-loop for ligand 4 has 
been discussed in the previous chapter. The interaction pattern formed in 
these complexes might explain the less enthalpic binding signal of 3 and 4 
compared to 1 and 2. 
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Figure 4: Comparison of ligand binding modes.
and 2 (blue) adopt a matching orientation of their corresponding atoms in 
the protein binding site. 
identical binding positions. 
and 2 (blue) from A together with ligand 
show that the hinge binding isoquinoline portion is slightly shifted. More 
importantly the sulfonamide portion is rotated aroun
modes from A and B (blue arrow).
and its Influence on 
Kinase-Ligand Interaction 
 A: Ligand 
B: Ligand 3 (red) and 4 (orange) both have 
C: Comparison and blow up of ligand 
3 (red) and 4 (orange) from B 
d 80° comparing binding 
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Figure 5. Superimposition
ligands. A: overall view of the protein. 
visualization of the polar protein
binding modes described in 
same binding mode also form an analogous interaction pattern with the 
protein. In the complex structures of 
into the active site through interactions with Thr51.
and its Influence on 
Kinase-Ligand Interaction 
 of the co-crystal structures of all four 
B: Blow up of the active site and 
-ligand interaction (dotted lines). 
Figure 4 can be observed. Ligands with the 
3 and 4 the Gly-loop is pulled down 
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The structural overview of the protein-ligand complexes in Figure 5A 
depicts that not only the ligand binding mode but also the overall structure 
of the protein can be divided into the two groups described above. Outside 
the active site the largest structural difference can be observed for the 
position of the the αC helix, the APE motif (not visible in Figure 5A) and 
the position of the protein-kinase-inhibitor-peptide (PKI). Hence, it appears 
that both, ligand 3 and 4 trigger a stong induced fit that locks the Gly-loop 
in a closed conformation. 
Unfortunately an extensive analysis of water molecules in the active site is 
not achievable in the presented cystal structures. Due to residual flexibility of 
the Gly-loop the electron densities of the water molecules in the active site 
are partially less well-defined. However it is clearly visible, that the 
additional propyl-sidechain of 4 leads to the displacement of a water 
molecule, which is well visible in the crystal structures of ligands 1, 2 and 3 
(Figure 6B). This is one explanation for the beneficial increase in entropy 
from 3 to 4, as the release of a fixed and well-ordered water molecule into the 
bulk water phase results in an entropically favored binding singnature. 
3. Enthalpy is Losing it: Stepwise Ligand Growth 
 
Figure 6. Crucial changes in the water structure. 
and 2; dotted lines indicate polar interactions; numbers indicate distances in 
Å. The presence of the additional methyl group in ligand 
of a water molecule. If r
complex of 1, the methyl
measure only 2.15 Å. The new position of the water molecule in the complex 
of 2 leads to a coordination with longer hydrogen bonds that is dominated by 
interactions with water molecules approaching the bulk phase 
entirely coordinated through ligand and protein interactions in the position 
observed for 1. The black arrow indicates the shift of the water molecule of 
2.4 Å. B: Comparison of 
in the complex structure of 
sidechain introduced in 
position (black arrow) and is replaced by the propyl
and its Influence on 
Kinase-Ligand Interaction 
A: Comparison of 
2 leads to the shift 
emaining in its original position as observed in the 
-carbon-to-water distance for ligand 
3 and 4; a clearly defined water molecule observed 
3 spacially overlaps with the additional propyl
4. Hence, the water molecule is displaced from its 
-sidechain of 
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The additional methyl group attached to 2 compared to 1 does not displace a 
water molecule from the active site but nonetheless seems to slightly shift a 
water molecule from its original position (Figure 6A). As a result, this 
water molecule is kept in position by longer hydrogen bonds and is 
dominated by interactions formed to other water molecules. This is in 
contrast to the coordination of the water molecule observed in the complex 
with 1, where all contacts are formed to either the ligand or the protein. 
Accordingly the binding of this water molecule in the complex of 2 
approaches more the situation of its release into the bulk phase. Thus, the 
entropically more favored signature of this complex appears reasonable, even 
though other cases have been described where the sole attachement of a 
methyl group was responded by a more enthalpically and less entropically 
favored signal.29, 30 
Amide T2 time does not indicate a difference in the dynamics of 
the different protein-ligand complexes. In order to analyse a potential 
difference in the residual flexibility of the different protein-ligand complexes 
15N-T2-relaxation NMR measurements were performed. The amide T2-time 
can be used as an indicator for protein backbone dynamics. The lower the 
measured T2-time the more rigid is the protein. The T2-time for 75 amino 
acids of PKA could be assigned and analyzed. The mean of these values gives 
an impression of the overall dynamics of the different protein-ligand 
complexes as shown in Figure 7. Evidently, no significant difference can be 
detected for the four different ligands. Data for ligand 4 was discussed in the 
previous chapter. Obviously, in the present case residual flexibility does not 
differ across the four protein-ligand complexes and hence, cannot provide an 
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explanation for the deviations and trends between the thermodynamic 
profiles of the different protein
Figure 7: 15N-T2-relaxation time in ms averaged over 75 amino 
acids for the different ligands, respectively. 
small. Error bars present the averaged standard deviation of the different 
amino acids. 
 
MD simulations reveal ligand solvation pattern
conformational and solvation properties of ligands in aqueous solution can be 
responsible for deviating thermodynamic profiles, a conformational ensemble 
of the unbound state was generated by 100 ns molecular dynamics 
simulations, separately for each ligand. It was found that the conformational 
diversity can be reasonably 
ensemble. A subsequent analysis of solvation thermodynamics using the 
GIST approach31, 32 
between the ligand molecules represented by their individual clusters. 
Specifically, the main clusters found for 
change in solvation entropy upon binding, which is triggered by a trapped 
water molecule in-between the sulfonamide and the terminal amine group. 
 it: Stepwise Ligand Growth and its Influence on 
Kinase-Ligand Interaction 
-ligand complexes. 
 
Overall differences are 
s. As differences in the 
approximated by three distinct clusters for each 
revealed deviating solvation entropy contributions 
3 and 4 seem to have a negative 
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However, there is a difference of this ligand-bound water molecule between 3 
and 4. The calculations revealed that ligand 3 entraps the water molecule in 
one of the three cluster representatives, corresponding to 40% of the 
simulation time. In the two other conformer clusters with 50% and 10% 
population, respectively, no water molecule is bound. Ligand 4 on the other 
hand, entraps a water molecule in all three major conformer clusters.  
Once the ligands are accommodated at the binding site these ligand-bound 
water molecules are released to the bulk phase. This may contribute 
favorably to the entropy binding component of 3 and 4 in direct comparison 
to 1 and 2. Furthermore, 3 entraps a water molecule less efficiently. 
Consistently, the entropic gain, as determined by ITC, for this ligand, is 
significantly smaller than for 4. 
Ligand performance put under the microscope. To analyze the 
development of ligand performance and characteristics upon ligand growth 
some descriptors, frequently consulted in FBDD were evaluated (Figure 
8).33, 34 In Figure 8A ligand efficiency (LE)35 as a measure for affinity per 
heavy atom and the binding efficiency index (BEI)36 as a measure of affinity 
per molecular weight are displayed. Both parameters are applied to define 
starting points in FBDD and record efficiency in fragment growth. No steady 
gain in affinity and LE or BEI is observed. In Figure 8B size-unbiased 
analyses of the ligands is displayed by fit quality (FQ)37, percentage ligand 
efficiency (%LE)38 and the size independent ligand efficiency (SILE)39. These 
evaluation methods are capable of comparing compounds at any stage of 
FBDD. Thereby the SILE value seems to be the most discriminating one, 
clearly pointing toward ligand 3 as the most favourable one. However, the 
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compound ranking appears to be similar for all three descriptors as they all 
score ligand 3 best. In Figure 8C lipophilic ligand efficiency (LLE)40 and 
logP/LE (LELP)41 values take the calculated logP values into account, 
thereby giving information on the lipophilicity in the process of lead 
optimization. For the LLE a higher value represents preferred characteristics 
whereas for the LELP a smaller value is advantageous. In both cases, ligand 
3 ranks best and ligand 1 second best. For the LLE, compounds 2 and 4 
rank equally unfavorable, whereas for the LEPL value ligand 4 ranks 
significantly worse than ligand 2. Hence ligand 3 represents the ligand with 
the most beneficial affinity-lipophilicity compromise. If we compare ligand 3 
to ligand 4, the graph shows that the increased lipophilicity of ligand 4 
through the addition of the propyl group is not overcompensated by a gain in 
affinity. Thus ligand 4 performs much worse than ligand 3 in this category. 
Figure 8D represents evaluation methods for entropic optimization. For this 
purpose the size-independent enthalpic efficiency (SIHE)42, the enthalpic 
efficiency (EE)43 and the specific enthalpic efficiency (specific EE)43 were 
calculated. For SIHE and EE the same trend is observed, even though the 
relative grading appears smaller for the size-independent value. The SIHE 
value takes into account that the maximally achievable pKH decreases with 
increasing molecular size. pKH is taken as a measure of the enthalpic 
component of binding and is defined as pKH=–ΔH/(2.303RT).  
In conclusion ligand 3 performs best in most plots. Hence, ligand 1 is 
optimized and grown to ligand 3 but the additional introduction of the 
propyl group of ligand 4 appears inadvisable. 
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Figure 8. Different evaluation methods to analyze fragment 
development applied for all four different ligands
were made according to the references using 
Classical Methods to prioritize the starting point in FBDD: Ligand 
and its Influence on 
Kinase-Ligand Interaction 
. Calculations 
ΔG [kJ/mol]
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efficiency35 and binding efficiency index36. B: Fit quality37, percentage ligand 
efficiency38, and size independent ligand efficiency39 as size-unbiased 
comparison of early stage hits in FBDD. C: Lipophilicity development in the 
optimization process: Lipophilic ligand efficiency40 and logP/LE41. D: Graphs 
focusing on enthalpic ligand optimization via Size independent enthalpic 
efficiency (SIHE)42 and enthalpic efficiency (EE)43 as well as specific 
enthalpic efficiency43 where enthalpic potency optimization is assigned to the 
number of potential hydrogen bond donors and acceptors in the ligand. 
3.6 Conclusion 
The change in the thermodynamic signature from ligand 1 to ligand 2 might 
result from the increase in polar buried protein surface, a tendency 
observable throughout the entire series. 
The entropically more favorable binding of 3 compared to 2 is most likely 
due to water displacement from the active site and water release from a 
conformer in solution prior to binding. MD simulations suggest that the 
ligand in solution partially entraps a water molecule. The release of this 
water molecule upon protein binding is entropically favorable. The 
explanation for the entropic gain of ligand 4 if compared to ligand 3 goes 
along the same direction. Calculations suggest that ligand 4 entraps this 
water molecule even more frequentely. Hence, the entropic benefit upon 
water release and ligand binding to the protein is even larger than for 3. 
The influence of the pronounced change in protein conformation observed for 
3 and 4 compared to 1 and 2 on enthalpy and entropy is difficult to 
evaluate. However, no impact results from the overall protein-ligand complex 
dynamics. 
In conclusion we observe a trend toward more entropic and less enthalpic 
binding upon ligand growing for the series of ligands presented in this study. 
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Thereby, affinity increases less due to partial enthalpy-entropy compensation. 
It has been suggested, that an enthalpically binding fragment is a more 
promising starting point in FBDD. Optimization for entropic reasons is 
usually more easily achieved than enthalpic improvement. It has been noted 
that fragments bind more enthalpy dominated, which is alluded to the 
formation of more optimal hydrogen bonds in an else hydrophobic 
environment (hot spot).6 
However, the effect of minor affinity gain upon fragment growth has also 
been observed in this context, being the complication that results from 
enthalpy-entropy compensation.5 
All in all, prediction of thermodynamic profiles remains challenging. This is 
also due to factors such as induced fits and changes in ligand binding modes 
upon ligand growth as presented in this study. Nonetheless it is highly 
interesting that we observe a gain in entropy of binding upon ligand growth 
even if the fragments are grown to relatively flexible ligands. 
3.7 Abbreviations 
Ala: alanine 
Asp: aspartate 
Arg: arginine 
ATP: adenosine triphosphate 
CHO: Chinese hamster ovary 
CSP: chemical shift perturbation 
DFG: aspartat-phenylalanin-glycin motif 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
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EDTA: ethylenediaminetetraacetic acid 
GIST: grid inhomogeneous solvation theory 
Gly: glycine 
Gly-loop: glycine-rich loop 
Glu: glutamate 
His-tag: histidine-tag 
ITC: isothermal titration calorimetry 
MBT: MES/Bis-Tris 
MD: molecular dynamics 
MPD: 2-methyl-2,4-pentanediol 
Ni-NTA: nickel-nitrilotriacetic acid 
NMR: nuclear magnetic resonance spectroscopy 
NPT: constant particles, pressure and temperature 
NVT: constant particles, volume and temperature 
PDB: protein data bank 
PKA: cAMP-dependent protein kinase 
PKI: protein kinase inhibitor 
qNMR: quantitative nuclear magnetic resonance spectroscopy 
Ser: serine 
TEA: triethanolamine 
TEV: tobacco etch virus 
Thr: threonine 
TLS: translation/libration/screw 
TROSY: transverse relaxation optimized spectroscopy 
Val: valine 
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3.9 Supplementary information 
Table S1.Crystallographic table for all crystal structures. Table spreads over two pages. 
Ligand, PDB entry → 3, 5M0B 2, 5M0L 1, 5M0C Apo, 5M0U 
Data collection & processing     
No. Crystals used 1 1 1 1 
Wavelength [Å] 0.97625 0.91841 0.91841 0.91841 
Space group 19 (P212121) 19 (P212121) 19 (P212121) 19 (P212121) 
Unit cell parameters: a, b, c [Å] 
β [°] 
57.9, 71.7, 109.9 65.8, 79.7, 84.5 72.4, 75.4, 80.2 58.2, 72.0, 109.8 
Diffraction dataa)     
Resolution range [Å] 45.08-1.51 34.09-1.47 43.75-1.73 45.27-1.67 
Highest shell resolution range [Å] 1.60-1.51 1.55-1.47 1.84-1.73 1.77-1.67 
Unique reflections 73047(11656) 75918(11950) 45445(7171) 53774(8345) 
R(I)sym [%]b) 5.4(49.8) 4.1(49.5) 3.8(48.0) 4.9(50.0) 
Completeness [%] 99.9(99.7) 98.7(97.4) 98.4(97.3) 98.4(96.0) 
Redundancy 7.3(7.3) 4.1(4.2) 4.5(4.6) 7.3(7.4) 
I/σ (I) 26.3(3.9) 19.1(2.7) 22.9(3.2) 22.4(3.7) 
Refinement     
Resolution range [Å] 39.88-1.51 32.9-1.47 37.68-1.73 45.27-1.67 
Reflections used in refinement (work/free) 69394/3653 72119/3799 43172/2273 52019/1755 
Final R values for all reflections (workc)/freed)) 
[%] 
13.2/15.4 15.3/17.3 17.3/20.0 15.2/18.9 
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Amino acids (PKA/PKI) 353/19 340/18 338/19 349/20 
Inhibitor atoms 17 2 x 15 14 - 
Water molecules 515 400 301 515 
RMSD from ideality     
Bond length [Å] 0.008 0.008 0.006 0.009 
Bond angles [°] 0.96 1.05 0.79 0.96 
Ramachandran plote)     
Residues in favoured regions [%] 91.5 90.6 91.5 91.2 
Residues in additionally allowed regions [%] 8.5 9.1 8.5 8.8 
Residues in generously allowed regions [%] 0.0 0.3 0.0 0.0 
Mean B-factors [Å²]     
PKA (protein)/PKI (peptide) 15.6/15.9 23.3/21.4 26.6 15.9 
Inhibitor 11.4 15.8/23.1 28.5 - 
Water molecules 28.3 32.4 36.9 28.3 
a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck.12 
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Table S2. All atoms of all ligands were 100% occupied. For visualiazation,
all three ligands are shown. 
Ligand 1, at 3.0 σ 
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Figure S1. ITC-titration curves for l
curves result from measurements with c-
values between 19 and 20. 
 
 
-Ligand Interaction
 
igand 01 in phosphate buffer as exemplary titration curves. 
values between 3 and 6, the lower three curves result from measurements with c
 
87 
Upper three 
-
3. Enthalpy is Losing it: Stepwise Ligand Growth and its Influence on Kinase
 
Figure S2. ITC-titration curves for l
titration curve (top, middle) results from a measurement with
with c-values of 10. 
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igand 02 in phosphate buffer as exemplary titration curves. 
 a c-value of 5. All other titrations result from measurements 
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Figure S3. ITC-titration curves for ligand 03 in phosphate buffer as exemplary titration curves. 
result from measurements with c-values between 45 and
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4 Surprising Non-Additivity of Methyl-
Groups in Drug-Kinase Interaction 
4.1 Annotations 
The following chapter will be published. The following people contributed to 
the paper and will therefore be listed as authors on the publication: 
Barbara Wienen-Schmidt‡, Denis Schmidt‡, Hans-Dieter Gerber‡, Andreas 
Heine‡, Gerhard Klebe‡* 
‡Institut für Pharmazeutische Chemie, Philipps-Universität Marburg, 
Marbacher Weg 6, 35032 Marburg, Germany 
* Corresponding author 
Protein expression for ITC and crystallization was performed by Barbara 
Wienen-Schmidt as well as ITC-measurements, crystallization and 
crystallography.  
Ligand synthesis and qNMR measurements were performed by Hans-Dieter 
Gerber 
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4.2 Abstract 
Drug optimization is guided by biophysical methods with increasing 
popularity. In the context of lead structure modifications, the introduction of 
methyl groups is a simple but potentially powerful approach. Hence, it is 
crucial to systematically investigate the influence of ligand methylation on 
biophysical characteristics such as thermodynamics. Here we investigate the 
influence of ligand methylation in different positions and combinations on 
drug-kinase interaction. Binding modes and complex structures were analyzed 
using protein crystallography. Thermodynamic signatures were measured via 
isothermal titration calorimetry (ITC). We found that not only position but 
also stereochemistry of the methyl group has an influence on binding potency 
as well as the thermodynamic signature of ligand binding to the protein. 
Strikingly, the combination of single methyl groups does not lead to additive 
effects. In our case the merger of two methyl groups in one ligand leads to an 
entirely new alternative ligand binding mode in the protein ligand complex. 
Moreover, the combination of the two methyl groups also resulted in a non-
additive thermodynamic profile of ligand binding. This unexpected drastic 
change in protein ligand interaction highlights the importance of 
crystallographic control even for minor modifications such as the introduction 
of a methyl group. 
4.3 Introduction 
In the process of drug design and drug optimization, lead structures can be 
decorated with diverse chemical functions in order to improve binding 
potency and biophysical characteristics. As a matter of fact, the design of 
drugs with tailored biophysical properties has become increasingly popular 
4. Surprising Non-Additivity of Methyl-Groups in Drug-Kinase Interaction 
92 
 
over the last years. 1-6 This development is based on the assumption that 
additional binding characteristics such as binding thermodynamics and 
kinetics might help to accelerate and improve the development and 
prediction of clinically successful drugs. Thereby, the introduction of a 
methyl group to a ligand is a very simple but potentially powerful approach. 
The importance but also the enormous popularity of methyl groups in drug 
design has been reported and reviewed previously.7, 8 The replacement of a 
hydrogen by a methyl group can significantly alter structure-activity 
relationships. These changes are based on improved electrostatics, modulated 
polarity and steric complementarity as well as conformational energetics and 
restrictions of the ligand. Furthermore, ordered water molecules in the 
protein active site that are replaced or shifted in consequence of the presence 
of a methyl group can take a major impact on structure-activity 
relationships.7 In rare cases, the introduction of an additional methyl group 
can even boost activity of a ligand 180 fold.7 On the other hand it can also 
reduce activity drastically if added at the wrong position.7  
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prominent kinase inhibitors: Fasudil and H-11529-17. In addition, we studied 
“intermediate” ligands showing methyl groups at different positions of the 
parent scaffold. An overview of the chemical structures of all five ligands is 
given in Figure 1. H-1152 (1) represents a dimethylated fasudil, fasudil 
(5) itself being the non-methylated reference ligand presented previously 
(Chapter 2). The two different single methylated ligands that derive from 
H-1152 are ligand 2 and 3. Ligand 2 is methylated at the 4 position of the 
isoquinoline portion and 3 is methylated at the 2 position of the 
homopiperazine ring. The latter methyl group in 3 introduces a stereogenic 
center which exhibits for both, 1 and 3, S-configuration. In order to evaluate 
the influence of this methyl group in inverted configuration, ligand 4 with R-
configuration was added to the panel. 
Crystal structures of all ligands depict differences in binding modes and 
suggest non-additivity with respect to the geometric influence of the two 
methyl groups. Non-additivity is also observed for the binding 
thermodynamics. Thermodynamic data was measured using isothermal 
titration calorimetry (ITC). Not only the binding potency ΔG is influenced 
by the different methylation patterns but also the partitioning in enthalpic 
and entropic contribution is altered. The crystal structure of the 
dimethylated H-1152 reveals an alternative binding mode compared to 
fasudil. Multiple crystal structures of bovine PKA, bovine PKA-mutants 
and rho-kinase 1 in complex with H-1152 have been published, however 
none of them reports this alternative binding mode as described in this 
report.18, 19, 13 Most interestingly, this binding mode is similar to that found 
with the kinase Roco4 in complex with H-1152. Roco4 is a model protein for 
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the human leucine-rich-repeat kinase 2 (LRRK2) which has been described to 
be involved in late-onset Parkinson.20  
Strikingly, this alternative binding mode is not observed for any other ligand 
of this series in complex with PKA. This drastic change in protein-ligand 
interaction is likely to cause a strong difference in ligand binding properties 
towards PKA. 
4.4 Experimental section 
Protein expression and purification 
The catalytic subunit of cAMP-dependent protein kinase from Chinese 
hamster ovary cells was expressed with a His-tag in a modified pET16b-
Vector with an introduced TEV-cleavage site between the protein N-terminus 
and His-tag. This plasmid was transformed into E. coli strain Bl21 
(DE3)/pLysS (Novagen).21 
Cell disruption was performed using a high-pressure homogenizer for multiple 
cycles. After centrifugation (1h at 30.000g) cell lysate supernatant was 
purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with a sodium chloride gradient.21 
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Crystallization 
Co-crystallization of 5 is discussed in Chapter 2. Co-crystallisation was 
performed using the hanging drop method at 4 °C. The crystallization drops 
contained the following ingredients: 10 mg/mL PKA (240 µM), 30 mM MBT 
(MES/Bis-Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM EDTA, 75 mM LiCl, 
0.03 mM Mega 8, 0.07 mM PKI (Sigma: P7739), 1.2 mM ligand dissolved in 
DMSO from a 50-100 mM stock. The well contained a mixture of methanol 
in water with varying methanol concentrations (v/v) for the different ligands 
(1: 18% methanol; 2: 20% methanol; 3: 16% methanol; 4: 19% methanol). In 
the crystallization setup, streak-seeding was performed with apo crystals by 
the help of a horse hair in order to initialize crystal growth. For crystal 
mounting, crystals were cryo protected in 5 mM MBT (MES/Bis-Tris buffer 
pH 6.9), 1 mM DTT, 0.1 mM LiCl, 1.2 mM ligand dissolved in DMSO from a 
50-100 mM stock, 16 % (v/v) methanol, 30% (v/v) MPD and flash frozen in 
liquid nitrogen. 
Crystallography 
Structures from 2 and 3 were collected at the storage ring Bessy II 
Helmholtz-Zentrum Berlin, Germany at Beamline 14.1 on a Pilatus 6M pixel 
detector. Structure from 1 was collected at the European Synchrotron 
Radiation Facility (ESRF) Grenoble, France at Beamline 14. Structure from 
5 is discussed in Chapter 2. 
The datasets were processed using XDS22 and molecular replacement was 
performed using CCP4 Phaser23 and PDB-structure of PKA from bos taurus 
1Q8W as a model. This was followed by simulated annealing, multiple 
refinement cycles of maximum likelihood energy minimization and B-factor 
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refinement using Phenix24. Coot25 was used to fit amino-acid side chains into 
σ-weighted 2Fo – Fc and Fo – Fc electron density maps. If appropriate 
electron density was observed, multiple side chain conformations were built 
into the model and maintained during the refinement if the minor populated 
side chain displayed at least 20 % occupancy. Ramachandran plots for 
structure validation were calculated using PROCHECK26. Data collection, 
unit cell parameters and refinement statistics are given in the supplementary 
information. Analysis of temperature factors was performed with Moleman27. 
Protein and PKI B-factors were anisotropically refined, water B-factors were 
isotropically refined for all structures. Decision for anisotropic or TLS 
refinement was based on comparison of Rfree. Anisotropic refinement was 
chosen over TLS if the achieved Rfree values were at least 0.5% lower for 
anisotropic than for TLS refinement. Rfree was calculated using 5% of all 
reflections which were randomly chosen and not used for the refinement. The 
required ligand restraint files were created using the Grade webserver28, 29. 
For figure preparation Pymol was used. Crystallographic tables as well as 
mFo-DFc-densities of the different ligands can be found in the supporting 
information. 
Isothermal titration calorimetry 
The buffer used for the ITC experiments contained: 30 mM sodium 
phosphate buffer pH 7.2, 10 mM MgCl2, 100 mM NaCl, 3% (v/v) DMSO. All 
measurements were repeated 3-5 times. Further buffers were used in order to 
check for protonation linkage. In these buffers 30 mM sodium phosphate 
buffer was replaced by 30 mM HEPES and 30 mM triethanolamine (TEA), 
respectively (both at pH 7.2). Buffer dependency was tested for all ligands 
and no significant buffer dependence could be detected. For the 
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measurements expressed, purified and dialyzed PKA was used in the ITC-
measuring cell. A 15-20 fold higher concentrated ligand solution, diluted in 
dialysis buffer, was then stepwise injected to the protein solution during the 
measurement. All measurements were performed at 25 °C. ITC data were 
analyzed using NITPIC and Sedphat30, 31. Raw data and exact values and 
standard deviations for ΔG, ΔH and -TΔS can be found in the 
supplementary information. 
Compound purity was analyzed using quantitative nuclear magnetic 
resonance spectroscopy (qNMR) and in case of deviation, ligand 
concentration was corrected accordingly.32 
Ligands 
Ligands 5 was purchased from Uorsy (Ukraine) and ligand 1 from Toronto 
Research Chemicals (TRC) (Canada). Ligands 2, 3 and 4 were synthesized. 
4.5 Results and discussion 
Crystal structures reveal surprising binding mode. Co-crystal 
structures with resolutions between 1.4 and 1.5 Å could be obtained. All 
structures were deposited in the protein data bank (PDB). The respective 
PDB-codes are listed in Table 1.  
Table 1. PDB codes of all five co-crystal structures. 
Ligand PDB-Code 
1 5M6V 
2 5M6Y 
3 5M75 
4 5M71 
5 5LCP 
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An overview and superposition of the different ligands is depicted in Figure 
2. The hinge binding mode of ligands 2, 3, 4 and 5 are all, as expected, 
similar (Figure 2A). Surprisingly, ligand 1 deviates from this pattern and 
populates two distinct binding poses (Figure 2B). Apart from the first 
orientation which agrees with the hinge binding mode observed for the other 
ligands, 1 exhibits a second, alternative interaction pattern with the hinge 
where the ligand is flipped over and rotated about 60°. Figure 3 displays a 
schematic overview of the hinge binding portion of the different ligands for 
ease of visualization. Interestingly the alternative binding position of 1 is the 
only position where a hydrogen bond between the sulfonyl-oxygens and the 
protein is formed. 
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While the homopiperazine portions of 1 (Figure 4A), 2 (Figure 4B) and 5 
(Figure 4E) form several direct hydrogen bonds to the protein, none are 
formed by ligands 3 (Figure 4C) and 4 (Figure 4D). However, all ligands 
form in all adopted poses a hydrogen bond between their respective 
isoquinoline nitrogen and the backbone nitrogen of Val123 which is part of 
the hinge region of the protein (Figure 4F). Interestingly, the conformation 
of the homopiperazine moiety of 3 corresponds exactly to that of 1, 
considering that both exhibit the same stereochemistry of the methyl group. 
However, the hydrogen bond of 1 to Glu127 does not occur in the complex 
with 3. This is due to the absence of the second alternative conformation of 
this amino acid in the complex of 3 which is found in the complex of 1 
(Figure 4A,C). 
For the other enantiomer of 3, ligand 4, the homopiperazine ring adopts a 
different conformation. In fact the ring conformation of 4 corresponds to that 
of fasudil (5) only having the nitrogen in another position. This altered 
nitrogen position of 4 leads to the disruption of the hydrogen bonds observed 
in the complex structure of 1. This leaves both the complexes of ligand 3 and 
4 with a total of a single hydrogen bond to the protein (Figure 4F).  
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Figure 5. Thermodynamic signatures for ligands 1
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Methylation at isoquinoline portion is most favorable. If 
thermodynamic binding profiles of the three differently singly methylated 
ligands are compared to that of the non-methylated fasudil (5), modulations 
in affinity as well as enthalpy and entropy are observed. Methylation solely 
at the isoquinoline moiety leads to an improved affinity for enthalpy reasons. 
One explanation might be an inventory of preferred ligand conformations in 
solution governed by the presence or absence of the methyl group. The 
rotatable bond between the isoquinoline portion and the sulfonamide group of 
the ligand allows multiple orientations of the homopiperazine moiety relative 
to the isoquinoline scaffold. In the crystal structures however, this 
multiplicity is reduced to only one of these orientations. Upon introduction of 
the methyl group at the isoquinoline moiety of ligand 2, the favored ligand 
conformation in solution might change. Due to steric reasons, the methyl 
group at the isoquinoline might promote a conformation where the 
homopiperazine portion is rotated away from the methyl group at the 
isoquinoline moiety. This conformation is close to the one in the crystal 
structure and hence makes the ligand conformation in the crystal structure 
enthalpically more favorable. Moreover, the methyl group is placed in a 
highly hydrophobic environment of the protein binding site (Leu49, Phe327). 
This enables the formation of additional van-der-Waals contacts between 
ligand and PKA without displacing a water molecule. Hence, this factor will 
promote enthalpy driven binding. 
Ligands 3 and 4 bind enthalpically less favorable than ligand 2. An 
explanation for this observation is the lack of polar H-bond interactions of 
the amino group in the methylated homopiperazine portion to the protein in 
both binding poses. Overall, 2 is the most potent inhibitor of this series. This 
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ligand profits from a beneficially positioned methyl group in the small 
hydrophobic niche, whereas the methyl groups introduced at the 
homopiperazine portion of 3 and 4 reduce binding potency, as the ring 
adopts in both cases an orientation that ruptures favorable H-bonds to be 
formed to Asp184 and Asn171 which is detrimental to the enthalpic 
contribution to binding. Remarkably, fasudil (5) which also establishes these 
H-bonds again experiences an enthalpic advantage compared to 3 and 4. 
Ligand 1 exhibits also a profile with an enthalpically less favorable binding 
and an entropic benefit. Only in the partially populated binding pose the 
enthalpically favorable H-bonds are formed, whereas the disorder over two 
binding modes provides this ligand with an entropic advantage. Therefore, 
the affinity gain of 1 is primarily entropy driven. 
4.6 Conclusion 
Our study shows that not only the region but also the stereochemical 
attachement of methyl groups matter for binding potency and the 
thermodynamic inventory. Combination of different ligand methylation sites 
does not necessarily lead to an additive effect on binding properties observed 
for the single methylation sites. As observed in our case, a combination can 
alter the ligand binding mode in a hardly predictable way. However, this 
might be the result of a combination of a favorable with an unfavorable 
ligand methylation. All in all, the data reveal the importance of region and 
stereochemistry as well as the combination of both by methylating a ligand. 
These factors are cruicial to take into account when optimizing ligands. 
Hence, continuous control of binding modes by crystallography is highly 
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advised in drug design, even for such small ligand alterations as 
methylations. 
4.7 Abbreviations 
Ala: alanine 
Asp: aspartate 
Arg: arginine 
ATP: adenosine triphosphate 
CHO: Chinese hamster ovary 
DFG: aspartate-phenylalanine-glycine motif 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
EDTA: ethylenediaminetetraacetic acid 
Gly: glycine 
Gly-loop: glycine-rich loop 
Glu: glutamate 
His-tag: histidine-tag 
ITC: isothermal titration calorimetry 
MBT: MES/Bis-Tris 
MPD: 2-methyl-2,4-pentanediol 
Ni-NTA: nickel-nitrilotriacetic acid 
PDB: protein data bank 
PKA: cAMP-dependent protein kinase 
PKI: protein kinase inhibitor 
qNMR: quantitative nuclear magnetic resonance spectroscopy 
Ser: serine 
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TEA: triethanolamine 
TEV: tobacco etch virus 
Thr: threonine 
Val: valine 
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4.9 Supplementary information
Table S1.All atoms of all ligands were 100% occupied. For visualiazation,
four ligands are shown. 
Ligand 1, at 3.0 σ 
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Table S2.Crystallographic table for all crystal structures. Table spreads over two pages. 
PDB entry → 1, 5M6V 2, 5M6Y 3,5M75 4, 5M71 
Data collection & processing     
No. Crystals used 1 1 1 1 
Wavelength [Å]  0.976250  0.918409 0.918409 0.918409 
Space group 19 19 19 19 
Unit cell parameters: a, b, c [Å] 58.5, 73.2, 108.8 58.7, 73.1, 109.3 58.7, 73.1, 109.3 58.7, 72.9, 109.9 
Diffraction dataa)     
Resolution range [Å] 45.71-1.42 45.77-1.37() 45.46-1.54() 42.23-1.49() 
Highest shell resolution range [Å] 1.50-1.42 1.45-1.37() 1.63-1.54() 1.58-1.49() 
Unique reflections 88220(13855) 98699(15403) 68403(10782) 77336(12077) 
R(I)sym [%]b) 4.5(47.6) 3.3(48.4) 5.7(48.6) 5.0(48.2) 
Completeness [%] 98.8(97.1) 98.7(96.5) 98.5(97.1) 99.0(97.0) 
Redundancy 7.3(7.3) 4.0(3.9) 3.9(3.9) 4.3(4.1) 
I/σ (I) 23.6(3.9) 20.1(2.3) 13.4(2.3) 15.20(2.4) 
Refinement     
Resolution range [Å] 45.71-1.42 45.77-1.37 41.94-1.54 42.23-1.49 
Reflections used in refinement (work/free) 83809/4410 93764/4935 64983/3420 73469/3867 
Final R values for all reflections (workc)/freed)) [%] 14.4/17.4 14.4/16.6 14.5/17.4 14.7/17.6 
Amino acids (PKA/PKI) 353/20 353/20 353/19 353/20 
Inhibitor atoms 22 21 21 21 
Water molecules 437 420 389 429 
RMSD from ideality     
Bond length [Å] 0.008 0.008 0.008 0.008 
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Bond angles [°] 1.034 0.989 0.973 0.960 
Ramachandran plote)     
Residues in favoured regions [%] 91.5 97.7 91.5 91.8 
Residues in additionally allowed regions [%] 8.5 7.3 7.9 8.2 
Residues in generously allowed regions [%] 0.0 0.0 0.6 0.0 
Mean B-factors [Å²]     
PKA (protein)/PKI (peptide) 21.6/23.6 24.1/24.2 24.0/23.2 24.8/24.8 
Inhibitor 18.5 20.6 18.5 22.9 
Water molecules 30.8 32.7 32.3 33.1 
a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck.26 
 
Table S3. Thermodynamic data and standard deviations for all five ligands. 
 
 
 
 
 
Ligand ΔG [kJ/mol] ΔH [kJ/mol] -TΔs [kJ/mol] 
1 -37.3±0.2 -26.2±0.9 -11.1±1.2 
2 -39.2±0.5 -39.1±1.5 -0.1±2.0 
3 -35.6±0.2 -29.0±0.5 -6.5±0.8 
4 -32.6±0.1 -28.2±0.6 -4.4±0.7 
5 -36.1±0.3 -33.1±0.4 -3.1±0.7 
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Figure S2. ITC-titration curves for l
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Figure S3. ITC-titration curves for ligand 03 in phosphate buffer as exemplary titration curves.
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Figure S4. ITC-titration curves for ligand 04 in phosphate buffer as exemplary titration curves.
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5 Small Changes, Big Effect: Variations in 
the Hinge Binding Modes 
5.1 Annotations 
Crystallization of all compounds and fragments was performed by Barbara 
Wienen-Schmidt. Structure refinement for all structures except for 
isoquinoline and adenine were entirely done by Barbara Wienen-Schmidt. For 
isoquinoline and adenine data processing and few cycles of automatic 
refinement were performed by Barbara Wienen-Schmidt. Final refinement 
was performed by Matthias Oebbeke in the framework of his Master thesis 
and crystallographic tables for these two compounds will be published in his 
thesis. 
5.2 Abstract 
Addressing the hinge binding motif is of utmost importance for the 
development of ATP-competitive kinase inhibitors. In this chapter, the 
influence of minor chemical changes and ligand fragmentation on the ligand-
kinase complex formation is investigated. Therefore, a series of ten ligands 
was crystallographically analyzed. The resulting structures and ligand 
binding positions were compared and could be classified into four groups 
showing different hinge interaction pattern. Strikingly, for specific ligands 
minor changes in chemical structure resulted in major changes in the ligand’s 
hinge binding mode. The same observation was made for fragments derived 
thereof. A subset of the fragments did not bind the hinge in the same way as 
the larger compound having the same fragment included. These findings are 
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highly relevant for drug optimization in a fragment-based drug discovery 
approach. Assumptions about conserved hinge binding modes upon ligand 
growing and evolvement have to be verified by crystallography. Moreover, 
the results of this study suggest that biophysical data such as 
thermodynamics or kinetics of protein-ligand complex formation should only 
be interpreted and correlated if a conserved position of the basic ligand 
binding scaffold has been crystallographically confirmed. 
5.3 Introduction 
As set out in the previous chapters, protein kinases are a major target in 
drug discovery. Different kinase inhibitor types have been developed, 
targeting active or inactive kinase conformation, in- or outside of the binding 
pocket.1 However, the majority of kinase inhibitors target the hinge region of 
the protein.2 The hinge region comprises the deeply buried far end of the 
active site of kinases. It connects the small N-terminal lobe with the bigger 
C-terminal lobe (Figure 1). Since the hinge binding portion of the ligand is 
crucial for ligand potency, most ligands that target the active site form at 
least one interaction with the hinge backbone. The hinge binding fragments 
themselves usually exhibit above average ligand efficiency compared to 
ligands evolved from this fragment as starting point. Therefore, the hinge 
binding motif is of utmost importance for affinity, but likely less for 
selectivity. Selectivity is predominately influenced by interactions to other 
protein areas such as the backpocket.3 Nevertheless, novel hinge binding 
scaffolds are important to enable novel intellectual property, which is why 
new hinge binding motifs are of particular interest for pharmaceutical 
companies.2  
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Physiologically, the backbone amide and carbonyl functions of the hinge 
region interact with the adenine portion of adenosine triphosphate (ATP) to 
recognize the substrate during the catalytic phosphorylation process. The 
unique feature of the hinge is the virtually linear arrangement of three 
functionalities: One donor function that is framed by two acceptor functions 
(Figure 2).4 The area around the hinge region is a hydrophobic cleft, which 
is why aromatic ring portions are preferred comprised in hinge binding motifs 
of potential drugs. Hydrogen-bond donors and acceptors within the 
heterocyclic ring system can form complementary polar interactions to the 
donor and acceptor functions of the hinge backbone.4 The goal is the 
formation of optimal hydrogen bonds in an else hydrophobic environment. 
This chapter focuses on the different hinge binding modes observed for 
different ligands that are derived from the drug fasudil as well as fragments 
thereof. Furthermore, hinge-binding modes of fragments deriving from ATP 
are discussed. Some of the ligands have already been presented in the 
previous chapters. 
Here, as well as in the other chapters, cAMP-dependent protein kinase 
(PKA) is used as a model protein. For PKA, the crucial part of the hinge is 
formed by the backbone carbonyl of Glu121 (acceptor 1), the backbone 
amide nitrogen of Val123 (donor) and the backbone carbonyl of Val123 
(acceptor 2) (Figure 2). The ligands presented here all interact with the 
donor function of Val123 and partially in addition with the acceptor function 
of Glu121. 
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Figure 1. Overview of 
(red) connects the small lobe
an important part of the catalytic cleft between the two lobes. 
Physiologically, the adenine
phosphate of ATP is then transferred to a substrate protein. The substrate 
protein binds in the region
mimicking a protein substrate and facilitates protein crystallization. 
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Figure 2. The hinge displays a nearly linear arrangement of three 
functionalities: The backbone carbonyl of Glu121 as an acceptor (1), the 
backbone amide nitrogen of Val123 as a donor and the backbone carbonyl of 
Val123 as a second acceptor.
 
Only minor chemical and structural modifications or fragmentation of the 
fasudil-and ATP-type li
differences in the hinge binding modes of several ligands. In the process of 
drug optimization and in fragment
the hinge binding modes are an often disregarded aspect. F
optimization, minor changes such as the addition of a hydroxyl or methyl 
group to the ligand are not expected to entirely change ligand binding 
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gands were made. Surprisingly, this led to strong 
-based drug design (FBDD), changes in 
 
 
or drug 
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behavior. Also in FBDD, fragments that are merged or stepwise grown to 
form drug-sized molecules are assumed to roughly remain in their original 
binding position when embedded into a larger scaffold.5-8 This study 
demonstrates that this assumption is too superficial. The crystallographic 
data presented here, demonstrates that fragments can have an unpredictable 
hinge binding behavior if compared to a larger scaffold having this fragment 
embedded as a key functionality. 
5.4 Experimental section 
Protein expression and purification 
The catalytic subunit of cAMP-dependent protein kinase from Chinese 
hamster ovary cells was expressed with a His-tag in a modified pET16b-
Vector with an introduced TEV-cleavage site between the protein N-terminus 
and His-tag. This plasmid was transformed into E. coli strain Bl21 
(DE3)/pLysS (Novagen).9 
Cell disruption was performed using a high-pressure homogenizer for multiple 
cycles. After centrifugation (1h at 30.000g) cell lysate supernatant was 
purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with a sodium chloride gradient.9 
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Crystallization 
Crystallization of hydroxyfasudil, isoquinoline, 1-aminoisoquinoline, 4-
quinazolamine and 5-isoquinoline carboxylic acid will be described in 
the following. Crystallization of all other ligands (fasudil, H-1152, 
isoquinoline-5-sulfonamide) has already been described in the previous 
chapters. 
Co-crystallisation was performed using the hanging drop method at 4 °C. The 
crystallization drops contained the following ingredients: 5-10 mg/ml PKA 
(120-240 µM), 30 or 110 mM MBT (MES/Bis-Tris Puffer pH 6.9) (110 mM 
MBT buffer was only used for 5-isoquinolinesulfonic acid and 5-
isoquinolinecarboxylic acid to buffer their acidity), 1 mM DTT, 0.1 mM 
EDTA, 75 mM LiCl, 0.03 mM Mega 8, 0.07 mM PKI (Sigma: P7739), 10 mM 
ligand dissolved in DMSO from a 50-100 mM stock. The well contained a 
mixture of methanol in water with varying methanol concentrations (v/v) for 
the different ligands (hydroxyfasudil: 14 % methanol; isoquinoline: 24 % 
methanol; adenine: 20 % methanol; 4-quinazolamine: 20 % methanol; 1-
aminoisoquinoline: 20 % methanol; 5-isoquinolinesulfonic acid: 11 % 
methanol; 5-isoquinolinecarboxylic acid: 24 % methanol). In the 
crystallization setup streak-seeding was performed with apo-crystals as seeds 
using a horse hair in order to initialize crystal growth. For crystal mounting, 
crystals were cryo protected in 5 mM MBT (MES/Bis-Tris Puffer pH 6.9), 1 
mM DTT, 0.1 mM LiCl, 10 mM ligand dissolved in DMSO from a 50-100 
mM stock, 16 % (v/v) methanol, 30% (v/v) MPD and flash frozen in liquid 
nitrogen. 
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Crystallography 
All cocrystal structures of fasudil, H-1152 and isoquinoline-5-sulfonamid 
are discussed in the second, third and fourth chapter. All other structures 
were collected at the storage ring Bessy II Helmholtz-Zentrum Berlin, 
Germany at Beamline 14.1 on a Pilatus 6M pixel detector. The datasets were 
processed using XDS10 and molecular replacement was performed using CCP4 
Phaser11 and PDB-structure of PKA from bos taurus 1Q8W as a model. This 
was followed by simulated annealing, multiple refinement cycles of maximum 
likelihood energy minimization and B-factor refinement with Phenix12. Coot13 
was used to fit amino-acid side chains into σ-weighted 2Fo – Fc and Fo – Fc 
electron density maps. If appropriate electron density was observed, multiple 
side chain conformations were built into the model and maintained during 
the refinement if the minor populated side chain displayed at least 20 % 
occupancy. Ramachandran plots for structure validation were calculated 
using PROCHECK14. Data collection, unit cell parameters and refinement 
statistics are given in the supplementary information. Analysis of 
temperature factors was performed with Moleman15. Protein and PKI B-
factors were anisotropically refined, water B-factors were isotropically refined 
for the structure of hydroxyfasudil. Structures of isoquinoline, adenine, 
1-aminoisoquinoline, 4-quinazolamine, 5isoquinoline sulfonic acid 
and 5-isoquinoline carboxylic acid were TLS-refined. For the definition of 
the TLS groups the TLSMD server was used.16, 17 Decision for anisotropic or 
TLS refinement was based on comparison of Rfree. Anisotropic refinement was 
chosen over TLS if the achieved Rfree values were at least 0.5% lower for 
anisotropic than for TLS refinement. Rfree was calculated using 5% of all 
reflections which were randomly chosen and not used for the refinement. The 
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required ligand restraint files were created using the Grade webserver18, 19. For 
figure preparation Pymol was used. Crystallographic tables can be found in 
the supporting information. 
Ligands 
Fragments isoquinoline, 1-aminoisoquinoline, 4-quinazolamine and 5-
isoquinoline carboxylic were purchased at sigma aldrich. Hydroxyfasudil 
was purchased at Toronto Research Chemicals (Canada). Vendors of all 
other ligands are listed in the previous chapters. 
5.5 Results and discussion 
A schematic overview of all ligands and their respective hinge binding pose 
relative to each other is presented in Figure 3 and Figure 4. Figure 3 
displays the hinge-binding fragments from fasudil, namely isoquinoline, 
and that of ATP, which is adenine. In addition, two fragments with an 
“intermediate” chemical structure of isoquinoline and adenine were 
investigated (1-aminoisoquinoline and 4-quinazolamine). For 
comparison, the crystal structure of ATP in complex with PKA from mus 
musculus deposited in the protein data bank (PDB) with the code 1ATP was 
analyzed.20 
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Figure 3. Schematic overview of the ligands and their respective 
hinge binding poses
binding fragment isoquinoline
fragment adenine are shown. In addition the two fragments with an 
“intermediate” chemical structure of isoquinoline and adenine, 
aminoisoquinoline and 
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orientation of its aromatic ring system as i
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Figure 4. Schematic overview of the ligands and their respective 
hinge binding poses
1152 as slightly modified fasudil
hinge binding mode. 
sulfonic acid bind with a similar hinge binding pose as 
sulfonic acid is replaced by a carboxylic acid
severely. The binding mode of 
rotation refer to the orientation of its aromatic ring system as indicated by 
gray arrows. Hydroxyfasudil
with a protonated nitrogen, this has been reported previously.
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ATP and adenine do not share a common hinge binding mode. The 
binding mode of the two hinge-binding elements of fasudil and ATP show a 
similar binding mode, the long axis through the adenine portion is only 
slightly rotated by about 15° compared to the orientation of the isoquinoline 
moiety of fasudil (Figure 5). Due to their similar position, these two hinge 
binding modes can be summarized as similar.  
Both ligands form a hydrogen bond to the backbone nitrogen of Val123. In 
addition, ATP interacts with acceptor 1 via its exocyclic amino function. 
However, if we compare the binding mode of ATP to that of its fragment 
adenine (Figure 6) it becomes apparent, that they do not share a common 
binding orientation. Adenine is flipped and rotated about 30°along its long 
axis compared to the adenine portion of ATP. The more, it is striking that 
the hinge residues which interact with ATP and adenine are identical. The 
deviating orientation results from the fact that adenine forms hydrogen 
bonds via its endocyclic N3 and N9 amino functionality. While in ATP the 
corresponding amino groups of N1 and the exocyclic NH2 function is used. 
Most likely due to the attached ribose-triphosphate moiety the binding mode 
adopted by adenine is not accessible for ATP. 
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Figure 5. Superposition of the co
fasudil and ATP. Crystal structure of 
mus musculus is taken 
hinge binding motifs of both ligands are similar. The adenine moiety is 
rotated about the long axis by 15° compared to the is
fasudil. Hydrogen-bond formation to Val123 is identical for both ligands. In 
addition, ATP-adenine interacts with the backbone carbonyl of Glu121.
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Figure 6. Superposition of the co
ATP and adenine. 
mus musculus is taken 
Compared to the adenine portion of 
30° about the long axis. However, hydrogen bonding partners provided by the 
hinge motif are equal in both cases. 
 
Fragments with the 
and isoquinoline display the same hinge binding mode as ATP.
contrast to adenine, the crystal structures of 
quinazolamine share a common hinge binding mode with 
and can be assigned to
absence of an appropriate amino group at the position of N3 and N9 in 
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adenine. For 1-aminoisoquinoline
formed if it adopted an orientation similar to that of 
In comparison, 4-quinazolamine
in position 1 of the quinazoline, yet the second nitrogen corresponding to the 
N9 position of adenine is absent. Hence, an analogous binding mode as 
observed for adenine
quinazolamine to the protein. Thus, the binding mode adopted by adenine 
would also be unfavourable for 
Figure 7. Superposition of the co
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Fasudil and part of its fragments share a common hinge binding 
mode. Upon comparison of the binding mode of fasudil and its two 
fragments isoquinoline-5-sulfonamide and 5-isoquinoline sulfonic acid, 
an identical position of their respective hinge binding moieties can be 
observed (Figure 8). Only the position of the sulfonamide and sulfonic acid 
functions differ slightly from that in fasudil, but they match very closely for 
both fragments. The reason for this rotation of the sulfonamide group in the 
isoquinoline-5-sulfonamide-PKA complex has already been discussed in 
chapter 3: For steric reasons only the small fragments can form an 
interaction to Asp127 with their respective sulfonamide portions. 
Nevertheless, it is interesting to see that the ligand with the sulfonic acid 
group as H-bond acceptor function, shares a common binding mode with the 
ligand possessing a sulfonamide as donor function at the same position. 
Fasudil and isoquinoline do not share a common binding mode. The 
compared binding modes of the smaller fragment isoquinoline and the drug 
molecule fasudil possessing an embedded isoquinoline moiety is shown in 
Figure 9. Interestingly, the isoquinoline is flipped and rotated by 60° along 
its long axis compared to the position of the isoquinoline moiety in fasudil. 
Nevertheless, the isoquinoline nitrogen remains in position, thereby keeping 
the hydrogen bond to the hinge region intact. This binding mode establishes 
a further class of hinge binding modes. 
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Figure 9. Superposition of 
fasudil and isoquinoline
is flipped and rotated 60° 
fasudil. 
 
The hinge binding mode of isoquinoline is 
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isoquinoline carboxylic acid
isoquinoline moiety in both structures (
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with an acceptor function in a similar position, does not share this hinge 
binding mode (Figure 
carboxylic acid is planar, the sufonic acid features a tetrahedral geometry. 
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carboxylic acid are identical to the second, alternative binding mode 
observed for the methylated fasudil
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energetically quite similar.
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Figure 11. Superposition of the co
5-isoquinoline sulfonic acid and 5
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Figure 12. Superposition of the co
isoquinoline and H
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fasudil.21 The binding mode to PKA from 
published.21 It corresponds to the binding mode we observed in the current 
study for PKA from Chinese hamster ovary (CHO). As 
the hinge binding motif is flipped and rotated by about 90°. The hydrogen 
bond to the donor functionality of hinge region (Val123) is formed via the 
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donates the hydrogen 
Glu121. The presence of this tautomer of 
fully aromatic isoquinolinol with 
been reported for this protein
Exhibiting a distance of 2.8 Å and 2.7 Å, both of the hydrogen bonds formed 
by hydroxyfasudil are comparable to the one of 
Figure 13. Superposition of the co
fasudil and hydroxyfasudil. 
is flipped and rotated 90° 
portion. It is the only structure where the isoquinoline
interact with the acceptor 
Val123 is formed by the oxygen of the isoquinolinone moiety.
 the Hinge Binding Modes
141 
hydroxyfasudil must be protonated, since it 
to the H-bond with the backbone carbonyl acceptor of 
hydroxyfasudil, in co
the deprotonated nitrogen, has previously 
-ligand complex.21  
fasudil (2.8 Å).
-crystal structures of PKA with
The isoquinoline moiety of hydroxyfasudil
around the long axis through the isoquinoline 
-nitrogen does not 
functionality of Val123. Instead a contact to 
 
 
ntrast to the 
 
 
 
 
 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
142 
 
5.6 Conclusion 
In total four different hinge binding modes could be defined for the 
structurally related scaffolds of quinoline or purine type. All of the scaffolds 
exhibit an isoquinoline, a quinazoline or purine-based moiety as a hinge 
binding motif. Binding mode one includes: Fasudil, isoquinoline-5-
sulfonamide, 5-isoquinoline sulfonic acid, ATP, 1-aminoisoquinoline, 
4-quinazolamine and one of the two alternative binding modes of H-1152. 
Binding mode two is adopted by isoquinoline, 5-isoquinoline carboxylic 
acid, and by the second binding mode of H-1152. The third binding mode is 
only represented by adenine and the fourth merely by hydroxyfasudil.  
Despite their structural similarity in terms of chemical formular, even closely 
related ligands or fragments thereof can exhibit striking and novel hinge 
binding positions. It is crucial to consider such aspects in the process of 
FBDD and drug optimization. Linking or growing fragments into potential 
drug candidates can change the behavior of the ligands’ key functions in a 
way that is still hardly predictable. 
Vice versa discrepancies in the binding modes of fragments and already 
characterized compounds (detected by approaches other than FBDD) having 
these fragments embedded could be exploited to create novel drug candidates 
with improved affinity. If a known compound (e.g. a high-throughput 
screening hit) is virtually fragmented and these fragments are then 
crystallographically analyzed, the potentially different binding modes of the 
fragments can provide ideas for an alternative connection of the different 
functionalities in a way that does not violate the crystallographically 
discovered fragment binding modes. Taking the isoquinoline fragment and 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
143 
 
fasudil as an example, the isoquinoline binding pose would suggest an 
attachement of the sulfonamide-homopierazine moiety at position C6 instead 
of C5 of isoquinoline. Using a novel topology possibly leads to new drug 
candidates with possibly improved or at least altered properties. Hence, new 
drug candidates could be developed from former high-throughput screening 
hits by fragmenting the latter and subsequently analyzing the corresponding 
fragment binding modes. Certainly, an optimized fragment linking strategy 
will not always be sterically possible and synthetically accessible. 
Nonetheless, in some cases this could even open a perspective for an easy 
road to success. 
Furthermore, this study underscores the importance of continuously 
controlling binding modes by crystallographic analysis. Interpretation of 
biophysical data such as thermodynamics or kinetics is pointless without the 
verification of a conserved overall ligand binding mode. For instance, 
thermodynamic profiles of adenine and ATP cannot easily be compared, 
simply because the binding pose changes. The same is true for isoquinoline 
and fasudil. Only if the key functionalities of the grown ligands and the 
initial fragments remain in unchanged position, development of 
thermodynamic and kinetic properties can be thoroughly understood. If key 
elements of the ligand binding modes change, too many factors influencing 
biophysical parameters will possibly overlap and complicate the picture. So 
far, it is impossible to clearly differentiate to what extend all the overlapping 
factors distort the readout of such experiments. 
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5.7 Abbreviations 
Ala: alanine 
Asp: aspartate 
Arg: arginine 
ATP: adenosine triphosphate 
CHO: Chinese hamster ovary 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
EDTA: ethylenediaminetetraacetic acid 
FBDD: fragment-based drug design 
Gly: glycine 
Glu: glutamate 
His-tag: histidine-tag 
MBT: MES/Bis-Tris 
MPD: 2-methyl-2,4-pentanediol 
Ni-NTA: nickel-nitrilotriacetic acid 
PDB: protein data bank 
PKA: cAMP-dependent protein kinase 
Ser: serine 
TEV: tobacco etch virus 
Thr: threonine 
TLS: translation/libration/screw 
Val: valine 
 
 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
145 
 
5.8 References 
1 Roskoski, R. Pharmacol Res 2016, 103, 26–48.  
2 Akritopoulou-Zanze, I.; Hajduk, P. J. Drug Discov Today 2009, 14, 
291–297.  
3 Klebe, G. Drug Design: Methodology, concepts, and mode-of-action; 
Springer Publishing Company, Incorporated, 2013; 599–640.  
4 Stroud, R., Finer-Moore, J., Eds. Computational and Structural 
Approaches to Drug Discovery; RSC Biomolecular Sciences; The Royal 
Society of Chemistry, 2007; 001–382.  
5 Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Nat Rev Drug 
Discov 2004, 3, 660–672.  
6 Hajduk, P. J.; Greer, J. Nat Rev Drug Discov 2007, 6, 211–219.  
7 de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. P. Drug Discov 
Today 2009, 14, 630–646.  
8 Erlanson, D. A.; Fesik, S. W.; Hubbard, R. E.; Jahnke, W.; Jhoti, H. 
Nat Rev Drug Discov 2016, 15, 605–619.  
9 Kudlinzki, D.; Linhard, V. L.; Saxena, K.; Sreeramulu, S.; Gande, S.; 
Schieborr, U.; Dreyer, M.; Schwalbe, H. Acta Crystallogr F Struct Biol 
Commun 2015, 71, 1088–1093.  
10 Kabsch, W. Acta Crystallogr D Biol Crystallogr 2010, 66, 125–132.  
 
 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
146 
 
11 McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; 
Storoni, L. C.; Read, R. J. J Appl Crystallogr 2007, 40, 658–674.  
12 Adams, P. D. et al. Acta Crystallogr D Biol Crystallogr 2010, 66, 213–
221.  
13 Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Acta Crystallogr 
D Biol Crystallogr 2010, 66, 486–501.  
14 Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. J 
Appl Crystallogr 1993, 26, 283–291.  
15 Kleywegt, G. J.; Zou, J.-Y.; Kjeldgaard, M.; Jones, T. A. In 
International Tables for Crystallography Volume F: Crystallography of 
biological macromolecules; Rossmann, M. G., Arnold, E., Eds.; Springer 
Netherlands: Dordrecht, 2001; 353–356.  
16 Painter, J.; Merritt, E. A. Acta Crystallogr D Biol Crystallogr 2006, 
62, 439–450.  
17 Painter, J.; Merritt, E. A. J Appl Crystallogr 2006, 39, 109–111.  
18 Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; 
Paciorek, W.; Vonrhein, C.; Bricogne, G. http://www.globalphasing.com.  
19 Bruno, I. J.; Cole, J. C.; Kessler, M.; Luo, J.; Motherwell, W. D. S.; 
Purkis, L. H.; Smith, B. R.; Taylor, R.; Cooper, R. I.; Harris, S. E.; 
Orpen, A. G. J Chem Inf Comput Sci 2004, 44, 2133–2144.  
 
 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
147 
 
20 Zheng, J.; Trafny, E. A.; Knighton, D. R.; Xuong, N.-H.; Taylor, S. S.; 
Ten Eyck, L. F.; Sowadski, J. M. Acta Crystallogr D Biol Crystallogr 1993, 
49, 362–365.  
21 Jacobs, M.; Hayakawa, K.; Swenson, L.; Bellon, S.; Fleming, M.; 
Taslimi, P.; Doran, J. J Biol Chem 2006, 281, 260–268.  
 
 
5. Small Changes, Big Effect: Variations in the Hinge Binding Modes 
148 
 
5.9 Supplementary information 
Table S1.Crystallographic table for all crystal structures. Table spreads over two pages. 
Ligand → Hydroxyfasudil 4-Quinazol-
amine 
1-Amino-
isoquinoline 
5-Isoquinoline 
sulfonic acid 
5-Isoquinoline 
carboxylicacid 
Data collection & processing      
No. Crystals used 1 1 1 1 1 
Wavelength [Å] 0.918409 0.918409 0.918409 0.918409 0.918409 
Space group 19 (P212121) 19 (P212121) 19 (P212121) 19 (P212121) 19 (P212121) 
Unit cell parameters: a, b, c [Å] 58.5; 72.9;109.5 58.1; 73.1;107.6 58.1; 73.1;107.6 58.3; 73.1;109.0 58.5; 73.3;109.5 
Diffraction dataa)      
Resolution range [Å] 45.61-1.53 45.47-1.71 45.48-1.69 45.601.79 45.70-1.88 
Highest shell resolution range [Å] 1.53-1.63 1.82-1.71 1.79-1.69 1.90-1.79 1.88-2.0 
Unique reflections 68873(10692) 45909(6206) 48217(6544) 43652(6891) 37996(5794) 
R(I)sym [%]b) 3.7(47.8) 4.5(39.6) 5.1(44.8) 5.1(47.8) 9.3(49.6) 
Completeness [%] 97.3(94.7) 91.8(77.9) 92.6(78.9) 98.0(97.2) 98.0(94.0) 
Redundancy 4.0(3.9) 4.1(3.1) 5.1(4.2) 4.2(3.7) 6.4(4.6) 
I/σ (I) 23.0(2.8) 19.4(2.4) 19.3(2.6) 19.4(2.6) 12.8(2.6) 
Refinement      
Resolution range [Å] 45.61-1.53 45.47-1.71 45.48-1.69 45.60-1.79 45.70-1.88 
Reflections used in refinement 
(work/free) 
 
65429/3444 43613/2296 45806/2411 41469/2183 36096/1900 
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Final R values for all reflections  
(workc)/freed)) [%] 
14.7/17.7 17.7/21.3 18.2/21.9 18.4/22.5 19.4/24.2 
Amino acids (PKA/PKI) 351/19 351/19 351/19 351/20 351/18 
Inhibitor atoms 21 11 11 2x14 13 
Water molecules 406 351 309 251 155 
RMSD from ideality      
Bond length [Å] 0.009 0.006 0.009 0.011 0.011 
Bond angles [°] 0.97 0.788 1.045 1.040 1.001 
Ramachandran plote)      
Residues in favoured regions [%] 91.5 91.4 90.4 90.5 90.0 
Residues in additionally allowed 
regions [%] 
8.2 8.6 9.0 8.6 9.1 
Residues in generously allowed 
regions [%] 
0.3 0.0 0.6 0.9 0.9 
Mean B-factors [Å²]      
PKA (protein)/PKI (peptide) 23.4/22.0 27.0/23.7 29.4/29.0 34.8/29.0 37.8/34.2 
Inhibitor 26.5 21.8 22.9 40.2/44.9 41.2 
Water molecules 32.7 32.5 32.4 33.0 30.9 
a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck.14 
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6 Kinase Screen: Targeting Compound 
Selectivity 
6.1 Abstract  
Modern drug design, is frequently guided by the assumption that strong 
enthalpic binders are more selective than less enthalpic binding ones. Using 
the example of the cAMP-dependent protein kinase we characterized the 
thermodynamic binding profiles of 15 structurally related ligands using 
isothermal titration calorimetry. These 15 ligands were then tested in a 
kinase screen consisting of 39 human protein kinases. In addition 
staurosporine was used as an unspecific reference in the screen. Selectivity 
data from the kinase screen were then faced with the thermodynamic profiles 
against PKA. Strikingly no clear-cut correlation between ΔH and ligand 
selectivity emerged from the analysis. The more it is surprising that the most 
enthalpic binder displayed the worst selectivity apart from stauropsorine. 
However, a correlation between ΔG and ligands selectivity could be shown. 
6.2 Introduction 
Kinases are a protein family of major clinical relevance. The human genome 
migh encode for up to 518 protein kinases, several of which might be of 
pathological relevance.1 In eukaryotes 30% of all proteins are temporarily 
reversibly phosphorylated, hence kinases are powerful switches to regulate 
activity regulation of signaling pathways. Anomalous kinase activity is 
particularly important in diseases that originate from inflammatory and 
proliferative responses. Examples are cancer, rheumatoid arthritis, 
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cardiovascular and neurological disorders, asthma and psoriasis. These 
implications make protein kinases a major target in drug design.2-4 
Classical kinase inhibitors bind competitively to the ATP-binding site. 
However, not only kinases, but approximately 3000 proteins encoded in the 
human genome, use ATP as substrate in various ways. Unfortunately, this 
bears the risk that developed inhibitors bind unselectively in competitive 
manner to the classical ATP-binding sites.5 This lack of selectivity is 
especially challenging across various members of the same kinase family as 
the target proteins. This is due to the pronounced structural similarity within 
the respective kinase families.  
Over the last years, different types of inhibitors have been developed to 
overcome this lack of selectivity. Kinase inhibitors are subdivided into type I, 
type II, type I I/2, type III, type IV, type V and type VI. Type I inhibitors 
represent the group of classical ATP-competitive inhibitors that bind to the 
active protein, adopting the so-called DFG-in conformation. All ligands 
considered in this study are such type I inhibitors. Type II inhibitors have 
come up over the last couple of years. They bind to the protein’s ATP-
binding site in its inactive DFG-out conformation. As the inactive 
conformation is less geometrically conserved than the active conformation, 
these ligands are expected to be more selective than type I inhibitors. 
For a DFG-out conformation, the DFG-loop and the corresponding 
phenylalanine are rotated away from the ATP binding site. Interestingly, not 
all kinases can adopt this conformation. So far no DFG-out conformation for 
PKA has been reported, thus it remains unclear if PKA can adopt this 
conformation. Type I I/2 inhibitors bind to an inactive conformation in the 
ATP-binding site that is, however, in DFG-in state. Type III inhibitors bind 
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adjacent to the ATP-binding site, whereas another allosteric inhibitor, type 
IV, binds far away from the active site. Type V inhibitors on the other hand, 
bind in a bivalent manner. The class of irreversible inhibitors is compiled 
through type VI inhibitors.6 
Over the last years, biophysical properties of ligands have become 
increasingly popular as descriptors to explain failure and success in 
subsequent clinical studies. In consequence, drug candidates are frequently 
selected with respect to these properties and often kinetic rate constants or 
thermodynamic properties are consulted in this context. It has been 
hypothesized that one of such properties, namely the enthalpic contribution 
to the thermodynamic binding profile of a ligand, is favorably correlated with 
the selectivity of this ligand.7 
Despite of this challenging hypothesis, the influence of the thermodynamic 
binding profile of putative drug candidates on their selectivity properties is 
still hard to estimate and needs a more in-depth investigation. This case 
study aims at providing data to shed some light on this promising hypothesis 
in terms of systematically collected experimental data. The hypothesis is 
tested for a series of compounds investigated in the previous chapters of this 
thesis. To do so, a kinase screen was performed, where 16 different ligands 
were tested (Figure 1) against 39 different kinases (Figure 2). 
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Figure 1: Overview of ligands tested in the kinase screen. 
discriminating structural moieties are highlighted in red.
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The kinases selected for this screen are uniformly distributed over the entire 
human kinome. About 8-9% of each kinase family was selected as 
representatives (Figure 2). As PKA belongs to the family of AGC-kinases, 
we allowed a higher percentage of 19% of AGC-kinases in the screen. The 
results from the selectivity screen were then faced with the recorded profiles 
from the isothermal titration calorimetry (ITC) experiments. The measured 
and calculated values for ΔG, ΔH, TΔS were each plotted against the results 
of the selectivity screen. Staurosporine was used as a known unselective 
reference in the kinase screen but has not been analyzed thermodynamically. 
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Figure 2: Overview of the human kinome.
this image of the kinome were considered in the kinase screen. Kinase families 
are assigned and differ in color. Adapted from Manning 2002. 
reproduced courtesy of Cell Signaling Technology, Inc. 
(www.cellsignal.com).1
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6.3 Experimental section 
Protein expression and purification 
The catalytic subunit of cAMP-dependent protein kinase from Chinese 
hamster ovary cells was expressed with a His-tag in a modified pET16b-
Vector with an introduced TEV-cleavage site between the protein N-terminus 
and His-tag. This plasmid was transformed into E. coli strain Bl21 
(DE3)/pLysS (Novagen).9 
Cell disruption was performed using a high-pressure homogenizer for multiple 
cycles. After centrifugation (1h at 30.000g) cell lysate supernatant was 
purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with a sodium chloride gradient.9 
Thermodynamics 
ITC measurements were performed as described in Chapters 2-4. 
Experimental values for all ligands can be found in the supplementary 
information. Detailed data including standard deviations and raw data for 
hydroxyfasudil is reported in the supplementary information as well. 
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Kinase Assay 
Kinases selected for the screen were retrieved based on literature data10-13 
and a binding site similarity comparison using Cavbase14. Thereby, kinases 
with published crystal structures were selected. One criterion of the literature 
search was based on data reporting kinases to be inhibited by either fasudil, 
H-1152, H-89 or hydroxyfasudil. These four drug candidates were the only 
compounds from our subset that have been previously subjected in kinase 
inhibition screens. This protocol guaranteed that solely kinases were selected 
which had been shown to be inhibited by at least one member of our subset 
of compounds. Hence, receiving results showing a modulation of kinase 
inhibition levels appeared more likely and the risk of recording no inhibition 
at all and hence no difference in selectivity profiles was reduced. A 
comparable percentage of kinases from each family were chosen, however, a 
twice as large percentage of entries from the AGC-kinase family were 
considered. 
Kinase inhibition assay was performed by Eurofins Pharma Discovery 
Services UK Limited. Details on the assay protocol are documented in the 
“KinaseProfiler Data Report Guide (v3)” as provided by the company. 
The performed activity assay is a radiometric kinase assay. All ligands were 
measured at a concentration of 50 μM. The respective kinase is incubated 
with a substrate peptide and radioactive ATP (Adenosine triphosphate, 
radioactive gamma phosphate) at a concentration corresponding to that of 
the Km-value of the respective kinase. In the catalytic process the radioactive 
gamma-phosphate of ATP is transferred to the peptidic substrate. The 
amount of transferred radioactive phosphate is then recorded. Upon 
inhibition of the kinase this catalytic process is hampered, resulting in a 
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signal decrease. All assays used for this inhibition screen involved direct 
measurement of substrate phosphorylation by the kinase under investigation 
and data was captured as duplicates. The raw data are measured by 
scintillation counting (in cpm). Positive control wells contain all components 
of the reaction except the inhibitor of interest; however, DMSO is included in 
these wells to control for solvent effects. Blank wells contain all components 
of the reaction with a reference inhibitor replacing the compound of interest. 
This calibrates kinase activity and establishes the base line (0 % kinase 
activity remaining). Results are expressed in terms of percentage of the mean 
kinase activity, with respect to the positive control samples. The positive 
control value is adjusted to be 100 %, and all test samples are reported 
relative to this value. For example, a result of 42 % means that, in 
comparison to the positive control, 42 % kinase activity remains in the 
presence of the test compound at a predefined concentration; or expressed 
differently, the test compound inhibits the kinase activity by 58 %. Residual 
activity percentages between 30 % and 70 % are considered partial hits. 
Beyond 30 % residual activity the tested compounds were classified as strong 
binders.  
Experimental values from the screen can be found in the supplementary 
information. 
6.4 Results 
The original data from the duplicate measurements of the kinase screen refer 
to the residual catalytic activity (in %) of the different 39 kinases tested. The 
amount of strongly inhibited kinases (residual activity: 0 % to 30 %) for the 
individual test compounds varies between 3 (8 % of kinases tested) for the 
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most discriminating compound 7 and 37 (95 % of kinases tested) for the 
known unselective ligand staurosporine. Across the entire study an average 
of 14 (36 %) strongly inhibited kinases is found which underlines the 
purposeful selection of the study sample (Figure 3). When considering both, 
strongly and partially inhibited kinases (from 0 % to 70 % residual activity) 
this distribution scatters from 14 (36 %, ligand 14) as minimum, to 39 (100 
% of kinases tested, staurosporine) as maximum, with an average of 24 (62 
%) inhibited kinases (Figure 3). Ligands that reduce activity of the majority 
of the regarded kinases (non-selective) and those that selectively block only 
few kinases are similar in both graphs. However, differences in selectivity 
between the ligands are more pronounced once the threshold is set to 30 %. 
According to this analysis the most selective inhibitors have to be assigned as 
7 and 14 as both strongly inhibit no more than 15 of the studied kinases. In 
contrast ligands H-1152, 17, H-89 and unsurprisingly staurosporine 
display the most unspecific inhibition profiles as they strongly inhibit at least 
50% of all 39 studied kinases. 
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Figure 3. Overview
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Table 1. Kinome trees based on inhibition data
Adapted from Manning 2002. Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com).
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Figure 4. Similar correlation diagrams are reported for ΔH and TΔS in 
Figure 5 and Figure 6, respectively. 
For ΔG and kinase selectivity a correlation is visible (Figure 4). The 
numerical correlation quality increases once data corresponding to 70 % 
residual activity are considered as threshold. This is indicated by an 
increasing R² value reported in Table 2. The R² value is the square of the 
Pearson product moment correlation coefficient. This value can be 
interpreted as the proportion of the variance in y (no. of inhibited kinases) 
attributable to the variance in x (ΔG, ΔH or TΔS respectively). Therefore, 
it is a measure for the numerical correlation. The closer R² approaches 1, the 
better the correlation can be estimated. A value close to zero indicates 
uncorrelated data. Usually R²=0.5 is considered the critical threshold for a 
given intrinsic correlation.15 
 
Table 2. R² values (square of the Pearson product moment 
correlation coefficient) for different potential correlations. R² is 
related to the quality of a correlation. Correlation quality of the different 
correlations of ΔG vs. selectivity increases with increasing threshold. The 
highest R² and hence the best correlation results from the data with the 70 % 
remaining kinase activity threshold. This means all kinases with a remaining 
activity of 70 % or lower are considered inhibited. 
Threshold R² of ΔG vs. 
selectivity 
correlation 
R² of ΔH vs. 
selectivity 
correlation 
R² of TΔS 
vs. selectivity 
correlation 
R² of MW vs. 
selectivity 
correlation 
30% 0.657 0.006 0.240 0.286 
40% 0.644 0.000 0.158 0.221 
50% 0.711 0.001 0.176 0.287 
50% 0.802 0.003 0.267 0.345 
70% 0.832 0.026 0.366 0.414 
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In addition, the number of inhibited kinases was plotted in dependence on 
the molecular weight (MW) of the different ligands (data not shown). The R² 
values are listed in Table 2 and indicate no significant correlation beyond 
R²>0.5 .R.  
6.5 Discussion 
The results from the selectivity screen show pronounced differences in the 
selectivity profiles within the presented ligand panel (Figure 3). This is the 
basis for our analysis to correlate selected biophysical descriptors that might 
influence these profiles.  
The data distribution across the kinase trees suggests that in particular 
members of the AGC-kinase familiy are inhibited by the ligands considered in 
this analysis. This is likely due to their similarity with PKA being a member 
of this family. Furthermore, in particular kinases from the CAMK- and 
CMGC-family were frequently inhibited. 
The observed correlation between ΔG and selectivity is in fact a sign for 
increasing unselectivity of all ligands with growing potency. It indicates that 
the weaker a ligand binds to PKA, the weaker it also binds to all other 
kinases. Vice versa ligands with high affinity to PKA also inhibit a fair 
number of all other kinases in the screen. 
The lack of correlation between MW and selectivity suggests that selectivity 
cannot be directly linked to the size or the degree of decoration of the studied 
ligands. 
The lack of a clear correlation between ΔH and TΔS versus selectivity is 
another important finding. To our opinion, as we observe a correlation with 
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ΔG, this lack of correlation for ΔH and ΔH is a direct consequence of 
enthalpy-entropy compensation indicated in our ITC data. Accordingly the 
very weak trends suggested by the reverse correlation of ΔH and TΔS 
supports this hypothesis. If we remove compounds 8 and 17 from the 
correlation the enthalpic binders show a trend toward higher selectivity. In 
contrast a more favorable entropic contribution to binding tends to yield less 
selective compounds. Remarkably ligand 17, arbitrarily removed from the 
analysis, binds enthalpically most favorable and is at the same time the most 
unselective inhibitor of the series. Ligand 8, another ligand deviating from 
the correlation, has been discovered as an entropically favored ligand. It 
induces a different conformation of the Gly-rich loop (Chapter 2), however, 
also ligand 5 induces this structural change (Chapter 3). Nevertheless, 
whereas 8 falls out of the series, ligand 5 matches well with trends suggested 
by the series. Thus, we believe a correlation between thermodynamic 
signature and selectivity suggested by an arbitrarily curated subset of the 
series is flawed. This observation finds its explanation in the fact that the 
thermodynamic profile is determined by multiple contributions arising from 
different steps of the complex formation process and not only from the 
interactions established by the ligands at the binding site. 
6.6 Conclusion 
Our aim was to collect some evidence for a putative correlation of 
thermodynamic properties of ligand-protein complex formation of one target 
kinase (PKA) with selectivity profiles of the respective ligands against a large 
panel of related kinases. We conclude that a significant correlation can only 
be observed between ΔG and selectivity. Remarkably, the overall selectivity 
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is reduced with increasing potency of the studied ligands against PKA. With 
some care, this might be interpreted as an indication for limited overall 
selectivity of the studied compound series. Nevertheless, it has to be 
reminded that particularly the regarded fasudil derivatives with attached 
methyl groups were developed and reported to show increasing selectivity.16-
18 On the other hand, at first glance, the most selective binders of the series 
are 7 and 14, two ligands classified to be of fragment size. Obviously, they 
show only potent binding against a limited number of kinases. In the current 
compound series additional decorations at the parent scaffold of the initial 
fragments results in a reduced selectivity discrimination against the studied 
kinase panel. 
ΔH and TΔS do not show any clear-cut correlation, possibly only certain 
trends emerge, if two compounds are arbitrarily removed from the 
correlation. Admittedly, the dataset evaluated in this case study is limited 
and not largely diverse. Thus, more comprehensive investigations need to be 
performed to validate the question about putative correlations with 
descriptors on a broader scope. Based on the current results it appears hardly 
justified to hypothesize that higher selectivity would generally correlate with 
enthalpically more favored binding. 
6.7 Abbreviations 
AGC: PKA, PKG, PKC containing group 
ATP: adenosine triphosphate 
CAMK: calcium/calmodulin-dependent protein kinases 
CK1: Casein kinase 1 containing group 
CMGC: CDK, MAPK, GSK3, CLK containing group 
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His-tag: histidine-tag 
ITC: isothermal titration calorimetry 
MW: molecular weight 
Ni-NTA: nickel-nitrilotriacetic acid 
R²: square of the Pearson product moment correlation coefficient 
TEV: tobacco etch virus 
TK: Tyrosin kinases 
TKL: Tyrosin kinase like group 
STE: Steril kinase homologue containing group  
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6.9 Supplementary information 
Table S1. Overview of thermodynamic and inhibition data. 
Phosphatpuffer Phosphatpuffer Phosphatpuffer No. of inh. kinases No. of inh. kinases 
MW [g/mol] ΔG [kJ/mol] ΔH [kJ/mol] -TΔS [kJ/mol] 70 % threshold 30 % threshold 
Fasudil 291.4 -36.1 -33.1 -3.1 24 11 
Hydroxyfasudil 307.4 -32.0 -30.1 -1.9 22 8 
H-1152 319.4 -37.3 -26.2 -11.1 33 30 
20 291.4 -31.9 -37.0 5.1 17 10 
21 291.4 -31.3 -35.7 4.3 18 8 
H-9 251.3 -35.4 -31.8 -1.3 23 11 
7 222.3 -27.9 -35.1 7.2 15 3 
8 293.4 -32.0 -22.8 -9.2 18 8 
10 293.4 -35.4 -35.1 -0.3 22 8 
14 208.2 -29.7 -38.7 9.1 14 6 
16 305.4 -35.6 -29.0 -6.5 27 14 
17 305.4 -39.2 -39.1 -0.1 36 30 
18 305.4 -32.6 -28.2 -4.4 23 10 
H-89 446.4 n.a. n.a. n.a. 32 22 
Aminofasudil 306.4 n.a. n.a. n.a. 19 8 
Staurosporine 466.5 n.a. n.a. n.a. 39 37 
n.a.: Data not available 
 
 
6. Kinase Screen: Targeting Compound Selectivity 
173 
 
Table S2. Overview of inhibition data (% residual activity) for all compounds and kinases. Kinase families are 
assigned. Table spreads over two pages. 
Kinase 
Family Kinase Fasudil 
Hydroxy-
fasudil H-1152 20 21 H-9 7 8 10 14 16 17 18 H-89 
Amino- 
fasudil 
Stauro-
sporine 
CAMK AMPK[alpha]2 51 63 4 48 65 40 72 64 47 75 14 4 42 5 76 -2 
CAMK BRSK2 32 43 4 38 53 39 60 62 41 58 17 5 40 18 63 0 
CMGC CDK5 57 67 11 36 39 29 54 54 69 61 36 3 42 31 103 0 
CMGC CDK6 88 99 100 91 104 126 95 100 101 110 94 60 93 87 99 -8 
CMGC CDK9 8 52 17 2 5 14 30 28 30 37 6 4 12 14 32 1 
CAMK CHK1 84 86 59 88 97 75 91 87 77 84 78 36 98 18 91 1 
CMGC CK2[alpha]1 97 97 90 90 91 88 107 88 95 91 86 42 61 90 86 42 
TK EphA2 70 96 1 79 85 82 91 72 65 85 67 2 75 39 73 -4 
TK FAK 65 69 3 82 86 71 86 78 67 85 54 5 72 11 62 -1 
TK Fes 57 54 7 73 78 68 83 78 80 83 70 5 63 12 58 1 
TK FGFR1 57 75 2 60 69 68 72 72 65 69 14 3 45 20 99 -1 
CMGC GSK3[beta] 101 97 84 97 102 92 88 90 92 92 95 70 82 91 93 0 
TKL IRAK4 85 102 87 87 99 75 95 92 91 72 93 41 79 65 52 -1 
TK JAK2 97 78 5 98 93 83 85 98 95 98 68 27 89 108 88 -4 
TKL LIMK1 67 79 6 71 59 72 61 77 53 71 50 10 35 8 71 -1 
STE LOK 53 85 12 86 71 72 80 93 73 87 73 8 63 53 71 0 
CAMK MELK 7 56 12 9 15 6 19 13 6 19 15 4 20 4 27 -1 
TK Mer 30 30 4 38 38 31 71 55 40 77 46 4 40 5 13 5 
TKL MLK1 43 63 12 79 76 78 69 82 83 64 65 4 57 50 66 -2 
CAMK MNK2 28 90 15 74 65 60 80 60 42 71 59 5 74 47 80 -1 
AGC MSK1 13 9 4 18 32 10 33 21 24 17 8 3 23 1 53 -1 
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Kinase 
Family Kinase Fasudil 
Hydroxy-
fasudil H-1152 20 21 H-9 7 8 10 14 16 17 18 H-89 
Amino- 
fasudil 
Stauro-
sporine 
STE MST2 75 49 13 86 76 58 78 77 84 75 59 9 79 44 94 2 
STE MST3 86 69 26 96 85 66 106 98 112 97 67 26 64 19 108 1 
AGC p70S6K 8 3 8 16 25 9 34 15 10 24 19 1 27 1 15 0 
STE PAK5 94 102 88 111 116 112 115 117 118 111 107 79 114 65 100 1 
AGC PDK1 76 84 12 102 107 66 104 99 88 94 67 17 86 115 107 -1 
CAMK PhK[gamma]2 63 67 3 72 85 28 90 59 50 70 35 4 70 26 80 0 
AGC PKA[alpha] 5 18 3 10 11 4 33 12 3 25 2 2 14 1 2 1 
AGC Akt1/PKB[alpha] 50 43 46 68 77 31 90 65 49 90 64 25 65 2 51 -1 
AGC Akt2/PKB[beta] 78 87 77 85 93 78 109 90 90 108 100 75 88 16 99 -1 
AGC PKC[epsilon] 40 68 8 38 44 36 68 57 59 81 24 8 45 36 28 0 
AGC PKN2/PRK2 3 4 3 5 7 3 20 11 10 24 2 3 6 1 4 1 
TK Ret 85 91 9 102 118 114 113 115 106 113 86 9 101 61 114 -3 
TKL RIPK2 92 98 65 83 92 99 88 91 99 79 91 45 99 89 90 4 
AGC ROCK1 21 16 3 20 32 30 54 47 33 45 7 9 28 8 7 0 
AGC ROCK2 1 0 2 2 3 2 4 7 2 4 0 2 1 1 1 1 
AGC RSK1/p90RSK 8 6 2 9 18 12 50 30 24 38 15 -1 22 2 69 0 
AGC RSK2 9 8 4 8 15 7 57 19 17 40 11 2 16 3 40 0 
CK1 VRK2 93 89 16 97 107 96 93 97 101 98 72 37 102 100 67 61 
 
Table S3. Thermodynamic data with standard deviations for hydroxyfasudil. 
 
Ligand ΔG [kJ/mol] ΔH [kJ/mol] -TΔS [kJ/mol] 
Hydroxyfasudil -32.0±0.5 -30.1±1.1 -1.9±1.6 
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Figure S1. ITC-titration curves for hydroxyfasudil
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7 Two Methods one Goal: Structural 
Differences between Results from Crystal 
Soaking and Co-crystallization 
7.1 Abstract 
This study focuses on the comparison of two popular protocols to produce 
crystals of protein-ligand complexes: soaking and co-crystallization. Both 
methods are applied to access information on protein-ligand interactions. 
This is of particular interest in structure-based drug design (SBDD). 
Thereby, soaking is the convenient and less time consuming method and 
hence widely applied. However, our study suggests, that crystal structures 
obtained by soaking can significantly differ from those received by co-
crystallization experiments. Co-crystallized structures are considered to be 
the more accurate and relevant representation of the equilibrium state in 
solution. We demonstrate that results from soaking experiments bear the risk 
to not only falsely represent the experienced protein-ligand interaction 
patterns and adopted protein conformations but even the ligand orientation 
in the active site. The impact of applied crystallization protocols is likely to 
depend on the change in protein conformation upon ligand binding. For 
kinases, which are particularly flexible proteins, a large induced fit triggered 
by the bound ligand reduces the structural agreement between crystal 
structures from soaking and co-crystallization. We conclude that the 
importance of the applied crystallization protocol must not be 
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underestimated. It can take crucial impact and must therefore be considered 
in SBDD.  
7.2 Introduction 
The protein discussed in this thesis is cAMP-dependent protein kinase 
(PKA). It is considered a typical representative of the clinically highly 
relevant class of protein kinases and is frequently used as a model protein. 1 
Kinases in general and specifically PKA are highly flexible proteins.2-4 In 
particular, the glycine-rich loop (Gly-loop) covering the active site can adopt 
multiple conformations.5 This property will be a key aspect for the present 
study. 
In the process of drug design and the search for new lead structures as well 
as lead optimization, protein crystallography is a commonly applied powerful 
tool to analyze drug binding to a target protein.6 The binding mode as well 
as non-covalent interactions such as salt bridges, hydrogen bonds and van der 
Waals interactions can be characterized and evaluated in terms of distances 
and angular relationships. Such information is crucial to guide modeling of 
drug properties. There are two commonly applied protocols to produce 
crystals of protein-ligand complexes for subsequent crystallographic analysis, 
namely co-crystallization and soaking.7 
For co-crystallization, protein and ligand are mixed in solution prior to the 
crystallization process. Upon crystallization the preformed protein-ligand 
complex from equilibrium conditions in solution assembles in the crystalline 
phase.7, 8 Due to the presence of the ligand and usually the presence of 
varying amounts of e.g. DMSO, a popular solvent for small organic 
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molecules, crystallization conditions can differ significantly for a series of co-
crystal trials using different ligands. Sometimes even screenings for a 
completely new condition are required. Therefore, the development of 
successful co-crystallization protocols can be a quite time and material 
intensive approach.  
Thus, especially in industry with the typically imposed time restrictions, the 
much faster soaking method is frequently applied. Here, the protein is 
crystallized in its uncomplexed state lacking any bound ligand. The 
premanufactured apo crystal is then placed into a droplet containing a high 
concentration of the targeted ligand for which the binding pose should be 
elucidated. The ligand may then diffuse into the crystal and bind to the 
protein. Prerequisite for the success of this procedure is the presence of 
sufficiently large water-filled channels passing contiguously through the 
packed crystal and accessing the binding site of the protein. Soaking is thus a 
fast method. It requires significantly less material than co-crystallization and 
builds on a well-established crystallization protocol.7, 8 Given that the apo 
protein crystallizes well, hundreds of differently soaked crystals can be 
generated from a single crystallization plate. Co-crystallization on the other 
hand can easily require multiple crystallization plates per ligand in order to 
find the optimized conditions, resulting in a high demand of protein and 
ligand material. 
Differences between crystal structures obtained from soaked crystals and 
from co-crystallization have been reported.9-13 However, the number of 
systematic and well-documented examples in literature is still surprisingly 
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small considering its importance for the relevance of the drug discovery 
pipeline. 
Meaningful examples are crystal structures of glutathione S-transferase of the 
malarial parasite plasmodium falciparum (PfGST) and lymphocyte-specific 
kinase (Lyck).12, 13 
Using a systematic approach, we will analyze the impact of the crystallization 
protocol on the protein-ligand complexation more thoroughly. Based on the 
obtained results we will put the important questions forward: How 
comparable are the binding modes received by the two different methods? 
Are they equally suited to represent the properties of the drug molecules in 
the bound state in solution? To tackle this question, we analyzed a series of 
ligands that are derived from the approved drug fasudil in complex with 
PKA. These ligands differ in their size as well as in their ability to trigger 
induced-fit adaptations of the protein.  
In general, the following restrictions must be considered in soaking: Large 
conformational changes induced by ligand binding may be difficult to 
experience in the solid state, cracking crystals or even dissolution can occur 
or access to the ligand binding site in the apo-crystal may be blocked.6 
Accordingly, it is recommended to cross-validate results from soaking 
experiments with co-crystals so that the full range of conformational changes 
can be discovered, particularly as co-crystal structures are considered to be 
the more relevant representation of the protein-ligand complex in 
equilibrium.7 Nevertheless, for most drug discovery studies results from 
soaking experiments are not cross-checked by co-crystallization attempts.  
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For our comparative study co
prepared and crystallographically analyzed. Striking differences between the 
two approaches were discovered. Especially for ligands tha
induced fit, soaked structures represent the ligand with a misleading binding 
mode, deviating interaction patterns and conformational differences of the 
protein structures. 
Figure 1. Overview of ligands used in this study. 
methylated form of fasudil. 
sulfonamide. 4: Long-chain 
short chained N-(2-aminoe
methylated N-methylisoquinoline
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purified in a first step using a Ni-NTA column that binds the His-tag of the 
protein and was eluted by an imidazole gradient. The His-tag was then 
cleaved off by TEV-protease. Afterwards, an inverse Ni-NTA column was 
employed collecting PKA in the flow-through. Finally, ion exchange 
chromatography was performed using a MonoS column separating three-fold 
phosphorylated PKA from the four-fold phosphorylated form using a HEPES 
buffer with sodium chloride gradient.14 
Crystallization 
All cocrystal protocols are also discussed in the previous chapters but are 
repeated in the following for improved comparability of the soaking and 
cocrystallization protocols. Crystallisation for soaking was performed using 
the hanging drop method at 4 °C. The crystallization drops contained the 
following ingredients: 10 mg/mL PKA (240 µM), 30 mM MBT (MES/Bis-
Tris Puffer pH 6.2-6.9), 1 mM DTT, 0.1 mM EDTA, 75 mM LiCl, 0.03 mM 
Mega 8, 0.07 mM PKI (Sigma: P7739 for co-crystals; Sigma: SCP0064 for apo 
crystals for soaking), 120µM or 1.2 mM ligand dissolved in DMSO from a 50-
100 mM stock for co-crystals but not for apo crystals. The well contained a 
mixture of methanol in water with varying methanol concentrations (v/v) for 
the different ligands (14-23% methanol). In the crystallization setup streak-
seeding was performed with apo crystals as seeds using a horse hair in order 
to initialize crystal growth. Soaking was performed in a buffer containing 30 
mM MBT (MES/Bis-Tris Puffer pH 6.9), 1 mM DTT, 0.1 mM EDTA, 75 
mM LiCl, 16 % methanol (v/v), 120µM ligand dissolved in DMSO for 24 
hours. For crystal mounting, crystals were cryo protected in 5 mM MBT 
(MES/Bis-Tris buffer pH 6.9), 1 mM DTT, 0.1 mM LiCl, 120µM or 1.2 mM 
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ligand dissolved in DMSO from a 50-100 mM stock, 16 % (v/v) methanol, 
30% (v/v) MPD and flash frozen in liquid nitrogen. 
Crystallography 
All cocrystal structures are discussed in the previous chapters. All soaked 
structures were collected at the storage ring Bessy II Helmholtz-Zentrum 
Berlin, Germany at Beamline 14.1 on a Pilatus 6M pixel detector. The 
datasets were processed using XDS15 and molecular replacement was 
performed using CCP4 Phaser16 and PDB-structure of PKA from bos taurus 
1Q8W as a model. This was followed by simulated annealing, multiple 
refinement cycles of maximum likelihood energy minimization and B-factor 
refinement with Phenix17. Coot18 was used to fit amino-acid side chains into 
σ-weighted 2Fo – Fc and Fo – Fc electron density maps. If appropriate 
electron density was observed, multiple side chain conformations were built 
into the model and maintained during the refinement if the minor populated 
side chain displayed at least 20 % occupancy. Ramachandran plots for 
structure validation were calculated using PROCHECK19. Data collection, 
unit cell parameters and refinement statistics are given in the supplementary 
information. Analysis of temperature factors was performed with Moleman20. 
Protein and PKI B-factors were anisotropically refined, water B-factors were 
isotropically refined for all soaked structures. Decision for anisotropic or TLS 
refinement was based on comparison of Rfree. Anisotropic refinement was 
chosen over TLS if the achieved Rfree values were at least 0.5% lower for 
anisotropic than for TLS refinement. Rfree was calculated using 5% of all 
reflections which were randomly chosen and not used for the refinement. The 
required ligand restraint files were created using the Grade webserver21, 22. 
For figure preparation Pymol was used. For RMSD calculation the iterative 
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alignment routine Matchmaker23 implemented in Chimera24 was used. 
Crystallographic tables of the different ligands can be found in the 
supporting information. 
7.4 Results 
Six different ligands were used in this comparative study. For each ligand 
complex a diffraction dataset could be collected using specimen obtained by 
the two crystallization protocols, resulting in a total of twelve structures. The 
superpositions of the respective structure pairs bound to the same ligand are 
shown in Figure 2-Figure 7. Figure 2 depicts fasudil in complex with 
PKA. The position of the glycine-rich loop (Gly-loop) is more open in the co-
crystal structure. In particular, this affects the residues Gly50 to Ser53, 
where backbone atoms are approximately shifted by 2 Å. Concerning the 
ligand, in particular the homopiperazine ring differs in position, mostly due 
to a deviating ring conformation. The root-mean-square deviation (RMSD) of 
the ligands between both structures amounts to 0.88 Å, the same value as for 
the CA-atoms of the protein. The two homopiperazine conformations lead to 
a difference in hydrogen bonding to the protein. In fact the co-crystal 
structure displays more polar interactions and involves Asp184 and Glu170 
whereas the soaked structure suggests an H-bond to Asn171.  
Figure 3 shows the binding modes for ligand 2. Here, the positions of the 
ligand match closer (RMSD: 0.64 Å). The position of the Gly-loop is not fully 
defined in the electron density for the soaked structure. Nonetheless, the 
amino acid residues of the loop visible in both structures share common 
positions. The RMSD of the CA-atoms of the protein is 0.65. In contrast to 
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1, the positions and conformations of the homopiperazine moieties adopt 
quite similar orientations.
 
Figure 2. Crystal structures of fasudil (1) in complex with PKA 
from a soaked (blue) and co
superposition indicates a slight rotation of the ligand from one to the other 
structure (RMSD ligand: 
0.88). B: Active site superposition. Dotted lines indicate hydrogen bonds. 
The position of the Gly
Furthermore, the co-crystal structure shows more hydrogen bonds b
the ligand and PKA.  
 
-crystallization 
184 
 
-crystallized structure (gray).
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Figure 3. Crystal structures of methylated fasudil (2) in complex 
with PKA from a soaked (violet) and co
(gray). A: Ligand superposition indicates a slight rotation of the li
from one to the other structure (RMSD ligand: 0.65 Å, RMSD of the CA
atoms of the protein: 0.64). 
indicate hydrogen bonds. The position of the Gly
soaked crystal structure. Hydroge
both structures.  
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Figure 4. Crystal structures of open chain fasudil
complex with PKA from a soaked (teal) and co
structure (gray). A:
whole ligand as well as an altered position of the aminoethyl moiety in the 
two structures (RMSD ligand: 1.20 Å, RMSD of the CA
protein: 0.94). B: Active site superp
bonds. The position of the Gly
structure. Hydrogen bonds are formed to different amino acids in the soaked 
and the co-crystal structure. In the co
formed to the hinge, the side chains of Asp 184 and Asn171 and the 
backbone of Glu170. In the soaked structure only the hinge and the backbone 
of Glu170 are addressed. An additional hydrogen bond is formed to the side 
chain of Glu127 in the soak
 Structural Differences between Results from 
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Figure 5. Crystal structures of long chain fasudil
complex with PKA from a soaked (yellow) and co
structure (gray). A: 
whole sulfonamide portion and the attached substituent of the ligand 
between the two structures (RMSD ligand: 0.91 Å, RMSD of the CA
of the protein: 0.65). 
hydrogen bonds. The position of the Gly
soaked structure. Strikingly, the positions of those residues visible in the 
soaked structure differ greatly from their position in the co
Only in the co-crystal structure an induced fit can be observed. The Gly
is pulled down into the active site. The hydrogen bond to Thr51 is only 
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structure from the soaked crystal. 
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Figure 6. Crystal structures of short chain fasudil
complex with PKA from a soaked (orange) and a co
structure (gray). A:
whole sulfonamide portion and the attached substituent of the ligand 
between the two structures (RMSD ligand: 1.26 Å, RMSD of CA
the protein: 0.61). B:
hydrogen bonds. The position of the Gly
crystal structure from the soaked crystal. Strikingly, the positions of those 
residues visible in the soaked structure (Thr51 and Gly52) differ 2.2
their backbone position from the co
structure an induced fit can be observed. The Gly
the active site. Hydrogen bonds are formed to different amino acids for the 
soaked (Val 123, Asp184, Asn171, Glu170) 
123, Thr51, Glu127). 
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crystallization protocoll, a strong induced fit takes place provoked by a pull-
down of the Gly-loop. This movement is triggered by the formation of a 
hydrogen bond between the ligand and Thr51 of the protein. It is absent in 
the soaked crystal structure. This in turn leads to an altered position of the 
ligand, where in particular the sulfonamide is conformationally rotated. The 
angle between the plane through the atoms of the isoquinoline moiety and 
the sulfonamide nitrogen is a suitable descriptor for this rotation. For the 
structure obtained by soaking this angle is 94° while it is only 26° in the same 
direction for the ligand in the co-crystal structure. The very same observation 
is made for 5 (Figure 6). The differences between the soaked and co-crystal 
structures are even more pronounced for this ligand. The rotated sulfonamide 
(angle between isoquinoline plane and the sulfonamide nitrogen bond vectors 
is 25° for co-crystal and 103° for soaked crystal, thus a similar situation as 
observed for 4) is accompanied by an aminoethyl moiety that points into the 
opposite direction. In the crystal structure resulting from soaking, only one 
hydrogen bond to the protein is formed whereas there are four present in the 
co-crystal structure.  
The binding mode of fragment-sized ligand 6 in Figure 7 is less influenced 
by the crystallization protocol. Both ligand binding mode and protein 
structure align well (RMSD ligand: 0.18 Å, RMSD of the CA-atoms of the 
protein: 0.44).  
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Figure 7. Crystal structures of fasudil
PKA from a soaked crystal (green) and a co
Ligand superposition shows an equal ligand binding conformation and 
position in both structures (RMSD ligand: 0.18, RMSD of CA
protein: 0.44). B: Active site superposition. Dotted lines indicate hydrogen 
bonds. The position of the Gly
bonding pattern between ligand and PKA are identical in both structures. 
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experiments this is different. Here the uncomplexed protein is arranged in 
premanufactured crystals and hence in a rather constrained environment 
when the ligand diffuses into the crystal with densely packed protein. The 
subsequent geometry established upon complexation and protein-ligand 
interactions are limited by this spatially restricted environment. Hence, an 
energetically favorable induced fit that requires an entire loop to alter its 
position cannot take place to the required extend.  
Crystal structures based on soaking bear the risk to suggest misleading 
binding modes particularly for flexible proteins such as kinases. Ligands 2 
and 3 demonstrate that flexible protein regions are more likely to be 
disordered in a soaked structure and accordingly not defined in the electron 
density. Ligands 4 and 5 indicate that a geometrically hampered protein 
adaption during the ligand binding process not only influences the number of 
observed interactions between ligand and protein but moreover influences the 
adopted bound conformation, the ligand binding mode and position. 
Therefore, crystal structures obtained by a soaking protocol can misdirect 
drug optimization and bias structure-based drug design (SBDD) by 
suggesting artificially distorted ligand binding modes. Co-crystallization on 
the other hand, depicts a ligand binding mode closer to the situation in 
solution: Flexible protein regions can adopt the optimal conformation 
yielding crystal structures with more reliable positions and improved 
visibility of these regions. Thereby they draw a more realistic picture of 
hydrogen bond formation in equilibrium between protein and ligand and 
more importantly ligand binding position. Our finding is strongly supported 
by one of our previous studies which analyzed the structural properties of the 
studied PKA complexes in solution by multidimensional NMR. Here we 
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recorded a convincing match between chemical shift perturbations of the 
kinase and geometrical differences observed among the complexes in 
cocrystallization. 
Our findings agree with results from other authors. For the kinase Lyck in 
complex with staurosporine the crystal structure resulting from soaking also 
underestimated the movement of the Gly-loop. The comparative co-crystal 
structure revealed a more prominent movement in this highly flexible protein 
region.12 
Ligand 6 on the other hand shows that the impact of the crystallization 
protocoll is minor for a fragment-sized ligand. We believe two reasons are 
important in that context. Firstly, due to their lower affinity fragments are 
usually not potent enough to induce larger changes in protein conformation. 
Second, the larger ligands 1-5 exhibit a fair number of torsional degrees of 
freedom that are rather soft, however allow the ligand to adopt to the packed 
protein environment in the premanufactured apo crystals during the soaking 
process. Fragments are usually selected to possess a much smaller number of 
torsional degrees of freedom. Hence, protein structures and ligand binding 
modes are more likely to be comparable in case of fragment complexes 
between crystal structures obtained by soaking and co-crystallization. 
Therefore, effort has to be made to promote and ease high throughput 
cocrystallization experiments. Various aspects involved in the 
cocrystallization process can be optimized. The utilization of robotic systems 
to pipette crystallization conditions reduces material consumption.25 
Moreover, strategies to reduce or remove the solvents used to solubelize the 
respective compounds can help keeping the crystallization conditions similar 
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to those of the apo crystals. Solubilizing the compounds in methanol and 
subsequentely allowing the methanol to evaporate on a crystallization plate 
prior to the addition of the crystallization drop is one approach.26 An analog 
dry-down procedure for the more popular solvent DMSO has also been 
decribed.27 In case of too low compound solubility, additives can increase 
compound solubility for an additional soaking after a cocrystallization 
prodcedure in order to increase ligand population in the binding site without 
altering the crystallization condition through the presence of the additive.28 
Finally, high throughput cocrystallization for fragment screening using 
acoustic droplet ejection, even allowing crystal growth on data collection 
media such as micro meshes, as published by Yin et al is a promising 
approach to promote large scale cocrystallization making cocrystallization 
screenings rapid and economic.29 An exemplified high throughput co-
crystallization experiment has been made by Ember and coworkers30. 
Performing a robotic co-crystallization screening campaign using 518 
compounds on the kinase BRD4-1 resulted in 377 successful crystallization 
approaches, yielding 194 structures leading to the identification of bound 14 
kinase inhibitors. 
7.6 Conclusion 
Because of its time and cost effectiveness, soaking is the more popular 
method to produce crystal structures of protein-ligand complexes. Here, we 
demonstrate that the more laborious method of co-crystallization is however 
the superior approach. In particular for flexible proteins, such as kinases, only 
co-crystallization can capture the actual ligand binding position and induced 
protein conformation. As we can take reference to NMR data collected on 
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some of the complexes reported in this study, we are very confident about 
this conclusion. The geometric discrepancies between structures generated 
from soaked crystals and co-crystallized ones appear to be smaller for 
fragment-sized ligand molecules with limited degrees of torsional freedom. 
However, for ligands that trigger conformational changes in the protein 
structure, soaking is definitely a misleading method. Soaking is likely to 
underestimate the number of polar interactions between protein and ligand 
due to inadequate, highly impaired positions of protein amino acid side 
chains and main chains. All in all, our study suggests that co-crystallization 
should be the gold standard to study protein-ligand complex formation. It 
provides structural information of the equilibrated protein-ligand interactions 
and complex conformation. This will be the only relevant basis to plan drug 
optimization as well as SBDD. Application of co-crystallization experiments 
can be promoted through optimization of co-crystallization protocols aiming 
at a reduction of material consumption and compound solvent content. 
7.7 Abbreviations 
Ala: alanine 
Asp: aspartate 
Arg: arginine 
BRD1-4: first bromodomain of bromodomain containing protein 4 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
EDTA: ethylenediaminetetraacetic acid 
Glu: glutamate 
Gly: glycine 
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Gly-loop: glycine-rich loop 
His-tag: histidine-tag 
Lyck: lymphocyte-specific kinase 
MBT: MES/Bis-Tris 
MPD: 2-methyl-2,4-pentanediol 
Ni-NTA: nickel-nitrilotriacetic acid 
PDB: protein data bank 
PfGST: glutathione S-transferase of the malarial parasite plasmodium 
falciparum 
PKA: cAMP-dependent protein kinase 
RMSD: root-mean-square deviation 
SBDD: structure-based drug design 
Ser: serine 
TEV: tobacco etch virus 
Thr: threonine 
TLS: translation/libration/screw 
Val: valine 
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7.9 Supplementary information 
Table S1. Crystallographic table for soaked crystal structures of Fasudil (1), 5 and 6. Table spreads over two 
pages. 
Ligand → Fasudil (1) 5 6 
Data collection & processing    
No. Crystals used 1 1 1 
Wavelength [Å] 0.918409 0.918409 0.918409 
Space group 19 (P212121) 19 (P212121) 19 (P212121) 
Unit cell parameters: a, b, c [Å] 58.3; 72.5;109.0 58.1; 72.3;108.8 58.3; 73.1;109.4 
Diffraction dataa)    
Resolution range [Å] 45.45-1.47 43.47-1.72 45.58-1.40 
Highest shell resolution range [Å] 1.56-1.47 1.82-1.72 1.48-1.40 
Unique reflections 79455(12522) 49381(7745) 91422(13988) 
R(I)sym [%]b) 3.5(47.8) 5.1(49.6) 4.9(46.7) 
Completeness [%] 99.7(98.4) 99.3(97.5) 97.9(93.7) 
Redundancy 6.6(6.5) 5.3(5.2) 6.5(6.2) 
I/σ (I) 27.6(3.8) 20.0(2.9) 19.0(3.0) 
Refinement    
Resolution range [Å] 30.85-1.47 41.81-1.72 36.56-1.40 
Reflections used in refinement (work/free) 75482/3973 46912/2469 86850/4572 
Final R values for all reflections (workc)/freed)) [%] 16.2/19.0 16.1/19.6 14.8/17.4 
Amino acids (PKA/PKI) 353/13 353/13 353/13 
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Inhibitor atoms 20 17 15 
Water molecules 306 257 380 
RMSD from ideality    
Bond length [Å] 0.006 0.005 0.008 
Bond angles [°] 1.078 0.908 1.186 
Ramachandran plote)    
Residues in favoured regions [%] 92.9 92.1 92.5 
Residues in additionally allowed regions [%] 7.1 7.9 6.9 
Residues in generously allowed regions [%] 0.0 0.0 0.6 
Mean B-factors [Å²]    
PKA (protein)/PKI (peptide) 28.3/28.6 31.5/35.7 22.7/23.7 
Inhibitor 33.7 29.5 19.0 
Water molecules 36.3 35.8 32.4 
a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck.19 
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Table S2. Crystallographic table for soaked crystal structures of 4, 3 and 2. Table spreads over two pages. 
Ligand → 4 3 2 
Data collection & processing    
No. Crystals used 1 1 1 
Wavelength [Å] 0.918409 0.918409 0.918409 
Space group 19 (P212121) 19 (P212121) 19 (P212121) 
Unit cell parameters: a, b, c [Å] 58.1; 72.4;108.7 58.3; 72.7;109.4 58.2; 73.2;108.5 
Diffraction dataa)    
Resolution range [Å] 45.34-1.42 45.46-1.58 43.58-1.67 
Highest shell resolution range [Å] 1.50-1.42 1.67-1.58 1.77-1.67 
Unique reflections 86529(13515) 62707(8401) 53731(8549) 
R(I)sym [%]b) 3.8(46.2) 5.6(49.5) 6.8(49.0) 
Completeness [%] 98.5(96.4) 96.6(81.1) 98.2(98.1) 
Redundancy 6.6(6.2) 4.9(4.6) 5.4(5.4) 
I/σ (I) 22.7(3.1) 15.7(2.4) 14.3(2.8) 
Refinement    
Resolution range [Å] 36.24-1.42 36.33-1.58 42.001.67 
Reflections used in refinement (work/free) 82202/4327 59571/3136 51044/2087 
Final R values for all reflections (workc)/freed)) [%] 15.1/18.0 15.7/19.7 16.0/20.0 
Amino acids (PKA/PKI) 353/13 353/13 353/13 
Inhibitor atoms 20 20 21 
Water molecules 303 347 247 
RMSD from ideality    
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Bond length [Å] 0.008 0.010 0.009 
Bond angles [°] 1.144 1.183 1.015 
Ramachandran plote)    
Residues in favoured regions [%] 92.5 93.4 90.6 
Residues in additionally allowed regions [%] 6.9 6.6 9.1 
Residues in generously allowed regions [%] 0.6 0.0 0.3 
Mean B-factors [Å²]    
PKA (protein)/PKI (peptide) 28.5/32.0 27.5/29.2 29.6/31.3 
Inhibitor 29.0 31.9 23.2 
Water molecules 36.1 35.1 33.2 
a)Numbers in parentheses are for the highest-resolution shell. 
b)Rsym=[ΣhΣi|Ii(h)−〈I(h)〉|/ΣhΣiIi(h)] × 100, 〈I(h)〉 is the mean of the I(h) observation of reflection h.  
c)Rwork=Σhkl|Fo−Fc|/Σhkl|Fo.  
d)Calculation of Rfree was performed as for Rwork but on 5 % of the data which was excluded from the refinement. 
e)Derived from Procheck.19 
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8 Summary (English) 
Over the last 20 years, the consideration of biophysical parameters such as 
kinetics and thermodynamics has been used to guide modern drug design. In 
contrast to the classical approach that mainly relies on affinity optimization, 
biophysical parameters allow a further discrimination of potential drug 
candidates with comparably high affinity. However, there is still a lack of 
systematic studies analyzing the impact of chemical ligand structure on, for 
example, thermodynamics. The studies presented in this thesis aim to bridge 
this gap. 
In this thesis a model protein, namely cAMP-dependent protein kinase 
(PKA) is used to gain particular insights into kinase behavior and 
thermodynamics upon ligand binding. Due to their implication in various 
diseases such as cancer, kinases are of utmost importance in drug design. 
The ligands used in this study were derived from the approved drug fasudil. 
They differ in their ligand degrees of freedom, molecular weight and 
decorations. 
Analyzing the impact of ligand degrees of freedom on the thermodynamic 
signatures, crystal structures were determined. The crystallographic analysis 
confirmed the flexible nature of the kinase. Particularly the position of the 
Gly-rich loop differs in the complex structures of ligands with varying ligand 
degrees of freedom. Thermodynamic signatures were determined using 
isothermal titration calorimetry. Remarkably, the ligand with the largest 
amount of internal degrees of freedom appeared to be the binder with the 
most beneficial entropic contribution. This counterintuitive observation is 
most likely the result of water displacement from the active site upon ligand 
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binding and due to a higher ordered local water structure of the ligand in 
solution prior to protein binding. 
For the series of ligands with increasing molecular weight, differences in the 
ligand coordination with the protein could be observed. A clear trend toward 
a more entropic and less enthalpic binding upon increasing molecular weight 
could be observed. Again, this results from structural changes and probably 
from the state of the uncomplexed ligand in solution, an utterly 
underestimated factor. 
For ligand decoration, introduction of methyl groups is a simple but 
potentially powerful approach. For differentely methylated ligands not only 
position but also stereochemistry of the methyl group has an influence on 
binding potency as well as the thermodynamic signature of ligand binding. 
Strikingly, the combination of single methyl groups does not lead to additive 
effects, neither in the binding mode visible in the crystal structure nor in the 
thermodynamic profile.  
Further decorations and fragments of fasudil and adenosine triphosphate 
(ATP) were crystallographically analyzed focusing on their interaction with 
the hinge region of PKA. It is a key point of attack of ATP-competitive 
kinase inhibitors. Even minor changes in chemical ligand or fragment 
structure, result in severe changes of the hinge binding pose of the respective 
binders. 
A kinase screen testing 16 ligands against 39 different kinases was performed 
in order to evaluate if thermodynamic properties can be correlated to the 
selectivity profile of a potential drug. Especially for kinases, selectivity is 
challenging but of utmost importance. Remarkably, only ΔG correlated well 
with the determined selectivity profiles. 
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Finally a methodology approach is presented comparing results from soaking 
and co-crystallization protocols. The results suggest that structural data from 
soaking experiments should ideally be verified by cocrystallization, since 
strong differences between the structures could be observed. 
There is still a lack of systematical studies correlating structural data, 
biophysical parameters and selectivity profiles of closely related ligand series. 
This is the only way to understand the interplay of these different factors, 
and only then biophysical parameters exceeding affinity information can 
reveal their full potential and predictive power for the selection of drug 
candidates. 
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9 Zusammenfassung (Deutsch/German) 
Seit rund 20 Jahren werden biophysikalische Parameter aus Thermodynamik 
und Kinetik immer häufiger verwendet, um die moderne Wirkstoffforschung 
zu verbessern. Im Gegensatz zum klassischen Wirkstoffdesign bei dem nach 
Affinitäten priorisiert wird, erlauben biophysikalische Methoden potentielle 
Wirkstoffkandidaten weitergehend zu differenzieren, auch wenn sie gleiche 
Affinitäten aufweisen. Leider werden mehr systematische Studien benötigt, 
die den Einfluss der chemischen Ligandstrukturen auf z.B. Thermodynamik 
untersuchen. Die vorliegende Arbeit zielt darauf ab diese bestehende Lücke 
zu verkleinern. 
In dieser Arbeit wird die cAMP-abhängige Proteinkinase (PKA) als 
Modellprotein verwendet um Details über das Verhalten von Kinasen und der 
Thermodynamik bei der Ligandbindung zu untersuchen. Da Kinasen eine 
wichtige Rolle in verschiedensten Krankheiten spielen (z.B. Krebs), sind sie 
von höchster Wichtigkeit in der Wirkstoffentwicklung. 
Die Liganden die in dieser Studie verwendet werden sind von dem 
zugelassenen Wirkstoff Fasudil abgeleitet. Sie unterscheiden sich von Fasudil 
in ihrem Molekulargewicht, der Anzahl ihrer Freiheitsgrade oder durch 
zusätzliche kleinere Substituenten. 
Um die Relevanz von Liganden Freiheitsgraden auf die thermodynamischen 
Profile bei der Protein-Ligand Bindung zu untersuchen, wurden 
Kristallstrukturen dieser Komplexe bestimmt. Die Kristallstrukturanalyse 
bestätigte die bereits bekannte strukturelle Flexibilität der Proteinkinase. 
Insbesondere die Gly-reiche Schleife zeigt in allen Kristallstrukturen eine 
gesonderte räumliche Position. 
9. Zusammenfassung (Deutsch/German) 
208 
 
Die thermodynamischen Signaturen wurden mit Hilfe der isothermen 
Titrationskalorimetrie gemessen. Bemerkenswerterweise zeigt der Ligand mit 
den meisten intrinsischen Freiheitsgraden, die entropisch vorteilhafteste 
Bindung an PKA. Dieses kontraintuitive Ergebnis ist vermutlich auf eine 
höher geordnete lokale Wasserstruktur des Liganden vor der Bindung, in 
Lösung, zurückzuführen.  
Für die Serie, die auf Liganden mit zunehmendem Molekulargewicht 
fokussiert ist, konnten Unterschiede in der Koordination des Liganden mit 
dem Protein beobachtet werden. Dabei zeigte sich in den thermodynamischen 
Profilen ein klarer Trend, bei dem mit zunehmendem Molekulargewicht der 
entropische Bindungsbeitrag stieg, während der enthalpische Bindungsbeitrag 
sank. Der Grund hierfür ist vermutlich ebenfalls der Zustand des Liganden in 
Lösung, ein Faktor der leider häufig unbeachtet bleibt. 
Methylgruppen sind einfache Substituenten, die dennoch eine große Wirkung 
haben können. Bei der Untersuchung von Liganden mit zusätzlichen 
Methylgruppen in verschiedenen Positionen stellte sich heraus, dass diese 
nicht nur einen Einfluss auf die Affinität sondern auch auf die 
thermodynamischen Signaturen haben. Interessanterweise hat die 
Kombination von verschiedenen Methylgruppen keinen additiven Effekt, 
weder bezüglich der Thermodynamik noch bezüglich des Bindemodus in der 
Kristallstruktur. 
Andere Substituenten und Fragmente von Fasudil und Adenosintriphosphat 
(ATP) wurden kristallographisch auf ihre Interaktion mit der Scharnierregion 
der PKA untersucht. Die Scharnierregion ist der wichtigste Angriffspunkt für 
ATP-kompetitive Hemmstoffe. Kleinste Änderungen der chemischen 
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Ligandstruktur führten zu starken Änderungen der Bindeposition und 
veränderten Interaktionen mit der Scharnierregion. 
Zur abschließenden Analyse wurde außerdem eine Kinase-
Selektivitätsuntersuchung mit 39 Kinasen und 16 Liganden durchgeführt. Die 
so erhaltenen Selektivitätsprofile wurden dann auf eine mögliche Korrelation 
mit den thermodynamischen Daten hin überprüft. Für Kinaseinhibitoren ist 
eine hohe Selektivität einer der herausforderndsten und wichtigsten 
Parameter. Bei der Analyse zeigte sich, dass ausschließlich ΔG gut mit den 
Selektivitätsprofilen korreliert. 
Des Weiteren wird in der Arbeit noch eine Methodenuntersuchung diskutiert, 
bei der Cokristallisation mit der sogenannten „soaking“ (engl. Durchtränken) 
Methode verglichen wird. Dabei konnten signifikante Unterschiede zwischen 
den resultierenden Kristallstrukturen beobachtet werden. Dies weist darauf 
hin, dass Ergebnisse aus „soaking“ Experimenten idealerweise durch 
Cokristallisation bestätigt werden sollten. 
Der Bedarf an weiteren systematischen Studien, die das Zusammenspiel von 
Struktur, biophysikalischen Daten und Selektivitätsprofilen von 
Ligandenserien untersuchen, ist nach wie vor hoch. Solche Daten sind die 
notwendige Voraussetzung um die Abhängigkeiten dieser Parameter 
voneinander zu verstehen. Nur so können biophysikalische Parameter 
wirklich zielgerichtet und gewinnbringend eingesetzt werden um verlässliche 
Vorhersagen über die Auswahl von potentiellen Wirkstoffkandidaten zu 
treffen. 
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